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61 ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of
cancer. Options for treatment are limited, and the only possibility of cure is
radical surgery combined with chemotherapy. Inflammation and tumor
stroma are important mediators in PDAC progression. Tumor-associated
macrophages  (TAMs),  among  other  cells,  create  an  immunosuppressive
microenvironment and enhance tumor progression. Because they pivotally
participate in tumorigenesis, TAMs are a potential target for therapeutic
intervention.
The  aim of  these  studies  was  to  explore  inflammation  and  TAMs in  PDAC.
Three  of  the  studies  were  conducted  in  cell  cultures,  and  one  was  a
retrospective clinical study. We polarized macrophages in cell cultures
towards inflammatory M1 and anti-inflammatory M2 phenotypes and
assessed  the  changes  in  the  signaling  pathways  and  the  effect  they  had  on
pancreatic cancer cell migration. We studied the association of preoperative
systemic  inflammatory  response  (SIR),  based  on  laboratory  data,  with  the
outcome of 265 patients with resectable PDAC.
Tumor-associated anti-inflammatory M2 macrophages promoted pancreatic
cancer  cell  migration  in  co-cultures  by  activating  their  MMP9  and  ADAM8
expression.  Support  of  the  pro-inflammatory  M1  phenotype  causes  these
macrophages  to  inhibit  cancer  cell  migration.   Several  intracellular  STAT
pathways and the NFkB pathway were activated by the interactions of cancer
cells and macrophages.
In preoperative laboratory data, patients’ elevated C-reactive protein (CRP),
an indicator of SIR, predicted worse postoperative survival. Moreover, low
levels of albumin, the most abundant protein in human blood circulation, as
well as elevated tumor markers CA19-9 and CEA, were associated with worse
survival.
These studies provide novel insight into the interaction of TAMs and PDAC.
The  results  encourage  further  research  into  TAMs  and  exploration  of  the
possibilities of skewing macrophage polarization toward the inflammatory M1
phenotype.   Development of  SIR seems detrimental  for  patients with PDAC
and predicts worse outcome. Preoperative CRP, in combination with albumin
and  tumor  markers  and  clinical  data,  could  prove  useful  when  evaluating
patients’ prognosis.
72 TIIVISTELMÄ (FINNISH ABSTRACT)
Haimasyövällä on huono alle 8% viiden vuoden kokonaiseloonjäämisennuste
ja se onkin Suomessa kolmanneksi yleisin syöpäkuoleman aiheuttaja.
Tulehduksen ja siihen liittyvien solujen, kuten makrofagien, on todettu olevan
oleellisena tekijänä haimasyövän invaasiossa. Kudoksissa verenkierrosta
saapuvat monosyytit erilaistuvat niiden mikroympäristön vaikutuksesta joko
inflammatorisiksi M1-tyypin makrofageiksi, jotka aktivoivat tulehdusreittejä
ja vastustavat syövän syntymistä ja etenemistä, tai anti-inflammatorisiksi M2
makrofageiksi, jotka puolestaan aktivoivat kudosten korjausmekanismeja ja
muun muassa verisuonien muodostusta. Syöpäsolujen läheisyydessä
monosyytit erilaistuvat tuumoriassosioiduiksi makrofageiksi, joiden on
todettu lisäävän haimasyöpäsolujen invaasiota ja jakautumista, sekä olevan
merkki huonosta ennusteesta. Tutkimuksen tarkoituksena oli tarkastella eri
tavoin erilaistettujen makrofagien ja haiman duktaalisen adenokarsinooman
välisiä vuorovaikutuksia. Lisäksi tutkimme ennen haimasyöpäleikkausta
otettujen peruslaboratoriokokeiden, erityisesti tulehdusmerkkiaineiden,
ennusteellista merkitystä haiman duktaalisessa adenokarsinoomassa.
Tutkimuksestamme saimme uutta tietoa haimasyöpäsolujen ja makrofagien
välisestä vuorovaikutuksesta. Havaitsimme, että soluviljelyissä M1-tyyppiset
makrofagit, jotka tuottivat tulehduksen välittäjäaineita, hidastivat
haimasyöpäsolujen vaeltamista viljelyalustoilla. M2 makrofagit puolestaan
lisäsivät syöpäsolujen liikehdintää aktivoimalla syöpäsoluissa matriksia
pilkkovien  proteiinien  kuten  MMP9  ja  ADAM8  eritystä.  Solujen  sisällä
haimasyöpäsolujen ja makrofagien STAT- ja NFkB-signalointireiteissä
tapahtui useita muutoksia solujen ollessa yhdessä viljelymaljoilla. Makrofagit
muun muassa lisäsivät huonoon ennusteeseen yhdistetyn STAT3:n
aktiivisuutta syöpäsoluissa.
Ennen haimasyöpäleikkausta otettuja verinäytteitä analysoimalla kävi ilmi,
että haimasyöpäpotilaiden yleistynyt tulehdusreaktio, joka voidaan todeta
muun muassa C-reaktiivisen proteiinin (CRP) kohonneena pitoisuutena,
ennustaa lyhempää leikkauksen jälkeistä elinaikaa. Lisäksi matala
albumiinitaso sekä kohonneet haimasyövän merkkiaineet (CA19-9 ja CEA)
olivat yhteydessä huonompaan ennusteeseen. Tulehdus- ja
syöpämerkkiaineet saattaisivat siis olla avuksi potilaiden ennusteen
arvioinnissa ennen haimasyöpäleikkausta. Tutkimuksemme kannustaa
jatkamaan tulehduksen ja haimasyövän välisten yhteyksien selvittämistä ja
etsimään makrofagien erilaistumiseen vaikuttamisen kautta mahdollisia
kohteita lääkehoidoille.
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5 INTRODUCTION
Pancreatic cancer is notorious for its dismal prognosis, with an overall 5-year
survival  rate  of  less  than  8%  (Siegel  2016).  Although  by  incidence  it  is  in
Finland only the tenth most common cancer in men and ninth in women, it is
still  the  third  most  common  cause  of  cancer  deaths  in  both  sexes  (Finnish
Cancer Registry). Pancreatic ductal adenocarcinoma (PDAC), accounting for
over 90% of pancreatic cancers, metastasizes aggressively in its early stages.
Other tumors of the pancreas have different prognoses and treatment
strategies (Fischer 2014 , Rezaee 2016), but the focus of this study is on PDAC.
The fundamental  causes of  pancreatic  cancer remain unclear.  It  usually  is  a
consequence  of  accumulating  gene  mutations  (Vincent  2011,  Ryan  2014).
Some of the eminent risk factors include smoking and chronic pancreatitis. In
the development and progression of pancreatic cancer, important components
emerging in the past two decades have been inflammation and the cells
associated with it, as well as stromal elements in the tumor microenvironment
(Coussens 2002, Elinav 2013, Atsumi 2014). Its prognosis is based on stage of
the disease, tumor-free resection margins, histological type and differentiation
of the tumor, lymph-node metastases, and tumor size.
Radical surgical resection accompanied by oncological treatment remain the
only chance for curative treatment; thus, early detection is crucial for the
patient’s  outcome.  The  central  anatomical  position  of  the  pancreas  enables
cancer to spread locally  to adjacent structures such as the duodenum, great
vessels, common bile duct, and peritoneum. Further, pancreatic cancer has a
high  tendency  to  spread  to  lymph  nodes  and  through  the  bloodstream  to
distant organs (Ryan 2014).
The  aim  of  this  study  was  to  examine  the  association  between  pancreatic
cancer and inflammation, and especially tumor-associated macrophages.
Review of the literature
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6 REVIEW OF THE LITERATURE
6.1 Anatomy and function of the pancreas
The pancreas lies retroperitoneally in the upper, central abdomen. Its central
position adjacent to large vessels such as the coeliac and superior mesenteric
arteries (which are partially responsible for the blood supply to the pancreas),
the abdominal aorta, inferior vena cava, and the splenic and superior
mesenteric  veins,  both  draining  into  the  portal  vein,  makes  the  pancreas  a
challenging  surgical  target  (Figure  1).  Anatomically,  the  pancreas  is  divided
into the head, body, tail, and the uncinated process. The main pancreatic duct
(duct of Wirsung) joins the common bile duct in the head of the pancreas and
leads the pancreatic and bile juices into the duodenum. The pancreatic tail is
adjacent to the spleen. Both sympathetic and parasympathetic nervous
systems innervate the pancreas (Textbook of Gastroenterology 2003).
The pancreas plays a critical role in food digestion and regulation of blood
glucose  levels.  Functionally  it  is  divided  into  the  exocrine  and  endocrine
pancreas. The exocrine pancreas (85% of all pancreatic tissue) synthesizes and
secretes  digestive  enzymes  such  as  amylase,  trypsin,  and  lipase,  into  the
duodenum. Pancreatic hormones (such as insulin, glucagon, somatostatin,
amylin,  and  pancreatic  polypeptide),  secreted  into  the  bloodstream  by  the
endocrine  pancreas  (comprising  the  islets  of  Langerhans),  are  among  their
other  functions  necessary  for  glucose  metabolism  (Textbook of
Gastroenterology 2003).
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Figure 1. Anatomy and surgical resectability of pancreatic cancer. Figure
reproduced with permission from Ryan DP, Hong TS & Bardeesy N 2014, "Pancreatic
adenocarcinoma", New England Journal of Medicine, vol. 371, no. 11, pp. 1039-1049.
Copyright Massachusetts Medical Society.
Review of the literature
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6.2 Epidemiology and survival of pancreatic cancer
Pancreatic  cancer  is  the  world’s  12th most  common  cancer  type  with
approximately 340 000 new cases annually. It is nevertheless the seventh
leading cause of cancer deaths worldwide with annual incidence and mortality
rates being close to equal (Ferlay 2014). Of the 46 cancer types studied in the
vast European population-based EUROCARE-5 study, pancreatic cancer had
the worst age-standardized 5-year relative survival of 6.7% (De Angelis 2014)
(Figure 2). In developed countries, pancreatic cancer incidence in 2012 was
8.6 in men and 5.9 in women per 100 000, with devastating mortality rates of
8.3  and  5.5.  In  less-developed  areas,  the  incidence  rate  is  3.3  and  2.4  with
equally grim mortality rates (Torre 2015).
Figure 2.  Stage distribution and 5-year relative survival rate of pancreatic
cancer patients by stage at diagnosis. Stage distribution do not sum to 100% due
to incomplete information.  The percentages are according to Siegel RL, Miller KD,
Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30.
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According to the Finnish Cancer Registry,  in Finland,  the pancreatic  cancer
age-adjusted incidence rate in 2014 was 8.9 for men and 7.6 for women per
100 000 being responsible for 3.4 to 3.8% of total cancer incidence (Table 1).
It  is  the  third  leading  cause  of  cancer  deaths  in  both  men  (after  lung  and
prostate cancers) and women (after breast and lung cancers), with mortality
rates of 8.9 and 6.5 (Finnish Cancer Registry 2015). Although still grim, the
pancreatic cancer prognosis has fortunately slowly improved; in Finland, the
age-standardized  overall  5-year  survival  rose  from  3%  (1999-2001)  to  6%
(2005-2007)  (p=0.002)  (Lepage  2015).  At  Helsinki  University  Hospital  for
those patients resected for PDAC between 2000 and 2013, the 5-year survival
rate  was  22%  and  at  10  years  14%  (Seppänen  2016).  PDAC  with  distant
metastases remains incurable, with a 5-year survival rate near zero (Siegel
2013).
Time period
1968-
1972
1973-
1977
1978-
1982
1983-
1987
1988-
1992
1993-
1997
1998-
2002
2003-
2007
2008-
2012
2013 2014
Male
Incidence 229 264 275 315 308 337 366 456 520 536 531
Incidence rate* 9.9 10.5 9.9 10.5 9.4 9.3 9.1 10.0 9.9 9.3 8.9
Mortality 216 249 256 293 292 309 344 415 474 503 538
Mortality rate* 9.3 9.9 9.3 9.7 8.9 8.5 8.5 9.0 8.8 8.6 8.9
Female
Incidence 207 255 316 356 398 405 424 512 553 575 601
Incidence rate* 5.8 6.3 6.7 6.8 7.0 6.7 6.6 7.4 7.4 7.5 7.6
Mortality 195 241 302 331 377 383 393 478 525 523 545
Mortality rate* 5.4 5.9 6.4 6.2 6.5 6.2 5.9 6.7 6.6 6.6 6.5
Table 1. The mean annual incidence and mortality of pancreatic cancer by time period. Source:
Finnish Cancer Registry, Cancer Statistics at www.cancerregistry.fi, updated 5 March, 2016
*Age-adjusted (to world standard population) rate per 100 000
Review of the literature
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6.3 Etiology
6.3.1 Risk factors
The causes of pancreatic cancer are multifactorial and complex, with precursor
lesions often preceding the cancer. Lifetime risk for pancreatic cancer is
approximately  1%  in  the  developed  world  (Torre  2015).  Advanced  age,
smoking,  chronic pancreatitis,  and a family history of  pancreatic  cancer are
consistently associated with increased risk for pancreatic cancer. Other, less
conclusive risk factors include diabetes mellitus, alcohol consumption,
obesity, chronic cirrhosis, western dietary habits, and various occupational
exposures.  More recently,  non-O blood group has also been associated with
increased risk for pancreatic cancer (Hassan 2007, Hidalgo 2010, Vincent
2011).
5.3.1.1 Age
Risk for pancreatic cancer increases with age, being extremely rare in patients
under  age  40.  The  median  age  of  onset  is  65  to  75  years,  with  over  80% of
patients diagnosed between 60 and 80 (Ghadirian 2003, Lowenfels 2006,
Raimondi 2007). Smoking and genetic disorders seem to be more prominent
risk factors for early-onset pancreatic cancer in younger than in older groups
(Raimondi 2007).
5.3.1.2 Genetic predisposition
Approximately 10% of pancreatic cancer patients have a family history of the
disease (Hruban 2010, Rustgi 2014). Even with only one first-degree relative
affected, risk for pancreatic cancer is approximately twofold, and is as many
as  57  times  higher  in  families  with  four  or  more  affected  members  than  in
unaffected families (Tersmette 2001, Klein 2004, McWilliams 2005). Of
patients with familial pancreatic cancer, a germline BRCA2 gene mutation has
been identified in 6 to 17% (Murphy 2002, Couch 2007) and germline PALB2
mutations  in  up  to  3%  (Jones  2009,  Slater  2010).  Some  of  the  known
hereditary cancer syndromes with an increased risk for pancreatic cancer are
in Table 2.
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Pancreatic cancer incidence is also associated with ethnic origin.  In the 1980's,
the  highest  incidence  rates  were  reported  in  New  Zealand  Maoris,  native
Hawaiians,  and African-Americans (Boyle 1989).  In a more recent overview
including  54  countries,  the  highest  mortality  rates  for  pancreatic  cancer  in
2007  were  among  men  in  the  Czech  Republic,  Hungary,  Slovakia,  and  the
Nordic  countries  (Bosetti  2012).  In  the  USA,  risk  for  pancreatic  cancer  is
considerably higher in the African-American population than in Caucasians
(Olson 2013, National Cancer Institute SEER 2015).
Furthermore, pancreatic cancer risk associates with ABO blood-types but the
mechanism is still undefined. Cohort studies indicate that patients with A, B,
and AB blood types have a significantly higher risk for pancreatic cancer than
patients with blood-type O (Egawa 2013, Wolpin 2009), and a genome-wide
association  study  reported  a  similar  association  (Amundadottir  2009).  In
resectable pancreatic cancer, blood-type O may even have a favorable impact
on prognosis (Ben 2011, Rahbari 2012).
Table 2. Hereditary cancer syndromes with increased risk for pancreatic cancer and affected genes.
Syndrome Affected Genes Fold Increase in Relative Risk
Hereditary breast and ovarian cancer BRCA 1 and 2 6-10
Peutz-Jeghers STK11/LKB1 132
Hereditary nonpolyposis colorectal cancer hMLH1, HMSH2, others 8-9
Hereditary pancreatitis PRSS1, PRSS2, SPINK1, CTRC 26-60
Cystic fibrosis CFTR 5-6
Familial atypical multiple mole melanoma CDKN2A 13-22
Familial adenomatous polyposis APC 4-6
Table reproduced with permission from Hidalgo, M. 2010, "Pancreatic cancer", New England Journal of
Medicine , vol. 362, no. 17, pp. 1605-1617, Supplementary Appendix.  Copyright Massachusetts Medical Society.
Review of the literature
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5.3.1.3 Chronic pancreatitis
Pancreatitis is an inflammation of the pancreas that can be divided into acute
and chronic types. It can result for example from alcohol abuse, gallstones, and
hereditary  syndromes.  Pancreatitis  can  also  be  an  early  manifestation  or  a
misdiagnosis of pancreatic cancer. Independent of the underlying cause, there
is,  nonetheless,  evidence  of  chronic  pancreatitis  as  increasing  risk  for
pancreatic cancer (Lowenfels 1993, Whitcomb 2002, Raimondi 2010),
although  only  4  to  6%  of  patients  with  chronic  pancreatitis  develop  PDAC
(Bang 2014). Typically PDAC appears about 10 to 20 years after the onset of
chronic pancreatitis. The mechanism underlying the association between the
diseases remains undetermined, and presumably comprises numerous steps
with increasing DNA damage. For instance, KRAS mutations in healthy
pancreatic tissue are very rare, but are common in chronic pancreatitis, and
some suggest that KRAS mutations may, with time, lead to the development
of pre-cancerous lesions (Whitcomb 2002, Raimondi 2010). Although chronic
inflammation of the pancreas raises the risk for pancreatic cancer, no definite
evidence exists that elevated circulating C-reactive protein (CRP) level, a
common indicator of systemic inflammation, is associated with increased risk
for PDAC (Douglas 2011, Bao 2013).
5.3.1.4 Diabetes mellitus
Diabetes mellitus (DM) is a metabolic disorder of the endocrine pancreas that,
if left untreated, leads to elevated blood glucose levels. It is caused by either
insulin deficiency (type 1 DM) or insulin resistance (type 2 DM). Type 2 DM is
typically associated with overweight and the unhealthy nutritional habits, now
with a rapidly rising incidence. Approximately 50 to 67% of pancreatic cancer
patients have DM (Chari  2005),  and studies have associated DM (primarily
type  2)  with  an  increased  risk  for  pancreatic  cancer  (Everhart  1995,
Giovannucci 2010, Batabyal 2014). The risk is greatest for a recently diagnosed
DM, with risk declining over time, thus leading to the hypothesis that DM is a
consequence,  or  an  early  indicator,  of  pancreatic  cancer.  Increased  risk  for
pancreatic cancer has, however, also occurred in patients with an over-10-year
history of  DM, indicating that  DM may also play a causal  role in pancreatic
carcinogenesis, possibly due to hyperinsulinemia, hyperglycemia, and
inflammation (Giovannucci 2010, Li 2011, Bosetti 2014). Especially late-onset
(>50 years of age) DM is associated with increased risk for pancreatic cancer,
although  only  less  than  1% of  these  subjects  actually  do  develop  pancreatic
cancer. Of the pancreatic cancer patients, 20 to 25% have developed new-onset
DM within 36 months prior to the cancer diagnosis (Chari 2005).
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5.3.1.5 Lifestyle-related risks factors
The lifestyle factor showing the most consistent link with increased risk for
pancreatic  cancer  is  smoking.  It  is  also  the  only  environmental  factor  with
evidence  of  a  causative  role,  accounting  for  some  15  to  20%  of  the  disease
(Hassan 2007, Iodice 2008, Lynch 2009). Smokers have about a 75% increase
in risk for developing pancreatic  cancer as compared to never-smokers;  the
risk falls to non-smoker levels within approximately 10 to 15 years after
quitting  (Iodice  2008,  Lynch  2009).  Evidence  of  passive  smoking  and
smokeless tobacco use as a cause is inconsistent (Duell 2012).
Obesity  has  become  an  increasing  problem  for  the  Western  world.  It  is
associated  with  increased  risk  for  pancreatic  cancer,  among  several  other
cancer forms, possibly by elevating insulin resistance and by causing
inflammation, even without the formation of diabetes mellitus (Gukovsky
2013, Preziosi 2014). Besides obesity, low physical activity and dietary factors
such  as  high  intake  of  red  meat,  a  high-fat,  high-cholesterol  diet,  and  low
intake of marine omega-3-poly-unsaturated fatty acids, fruits, and vegetables
may contribute to an increased risk (Ghadirian 2003, Raimondi 2009, Barone
2016).  The  role  of  vitamin  D  in  risk  for  pancreatic  cancer  is  controversial.
Although epidemiological studies show vitamin D deficiency and low exposure
to ambient ultraviolent radiation (sunlight) to be associated with increased
risk, dietary intake of vitamin D has shown no association or even an adverse
effect on risk for pancreatic cancer (Barreto 2015, Barone 2016).
The  verification  of  heavy  alcohol  consumption  as  independently  leading  to
pancreatic  cancer formation has been inconclusive.  Evidence from a pooled
meta-analysis suggests that chronic heavy alcohol consumption (>30–
40?g?alcohol/day) probably elevates risk (Duell 2012). Further, various
occupational exposures to such substances as metals, chlorinated hydrocarbon
solvents, and ionizing radiation may increase risk (Ojajarvi 2000, Alguacil
2003, Santibanez 2010). In contrast to what was initially suspected, neither
coffee nor caffeine is associated with increased risk for pancreatic cancer
(Dong 2011, Turati 2012, Bhoo-Pathy 2013).
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6.3.2 Prevention and screening
Since pancreatic cancer is a significant cause of death worldwide, and options
for treatment are limited, prevention and early detection are key factors in its
management. Unfortunately, as the causes are complex, multifactorial, and in
part unknown, prevention is complicated. Crucial to the prevention is tackling
the major lifestyle risks: smoking, diabetes, obesity, excessive alcohol
consumption, and alcohol-related chronic pancreatitis. Further, the high
prevalence of these risk factors presents an obstacle to screening (Vincent
2011).
When treating DM, it seems that metformin (but not insulin) may reduce the
risk for pancreatic cancer (Giovannucci 2010, Soranna 2012, Bosetti 2014).
The  current  consensus  recommends,  however,  that  cancer  risk  should  not
affect one’s choice of diabetes therapy, at least unless the patient is at very high
risk for cancer (Giovannucci 2010). Associations between inflammation and
cancer  have  led  to  investigation  of  anti-inflammatory  drugs  in  cancer
prevention, but with inconsistent findings concerning effects of acetosalicylic
acid (aspirin) in lowering pancreatic cancer risk (Larsson 2006, Tan 2011, Cui
2014, Yue 2014).
Screening for pancreatic cancer is problematic. As pancreatic cancer
metastases eagerly, and its prognosis is dismal in the advanced stages,
pressure is on to find early precursor lesions. This leads, though, to a risk of
overtreatment. Further, since pancreatic cancer incidence is relatively low,
and no simple and accurate screening method exists, we have no capacity to
screen all individuals at slightly increased risk. Therefore, researchers strive to
assess the best screening protocol for high-risk populations, such as those with
a genetic predisposition or patients over age 50 with new-onset diabetes and a
smoking history. In several studies, the most favorable screening method
seems to be magnetic resonance imaging (MRI) or magnetic resonance
cholangiopancreaticography (MRCP) (Bruenderman 2015, Del Chiaro 2015).
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6.4 Pathogenesis
6.4.1 Precursor lesions
Preceding the development of invasive pancreatic cancer emerge progressive,
non-invasive precursor lesions (Koorstra 2008a). The most common are
pancreatic intraepithelial neoplasias (PanINs) (Koorstra 2008b). PanIN
lesions are atypical, non-invasive, microscopic (<5 mm) duct lesions classified
into  three  grades  according  to  the  level  of  their  epithelial  atypia,  acquiring
cumulative  genetic  alterations  as  they  progress.  The  higher  the  PanIN
classification grade, the closer the lesion is to evolving into invasive carcinoma.
The pancreas, with increasing age, often contains low-grade PanIN-1 lesions,
most of which never develop into invasive carcinomas. Molecular biomarkers
and imaging are under investigation to detect pre-malignant PanIN lesions,
but although some promising markers (such as non-coding microRNAs) have
been detectable, they have not yet been adapted for clinical use (Haugk 2010).
Intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic
neoplasms (MCNs) are cystic tumors of the pancreas that can also evolve into
PDAC (Dudeja 2015). In contrast to PanINs, they are macroscopic, and may
be  detectable  by  radiological  imaging  techniques  such  as  computed
tomography  (CT).  They  form  a  spectrum  of  cystic  lesions  from  mild  atypia
(adenoma), moderate dysplasia (borderline), high-grade dysplasia (carcinoma
in situ), to invasive carcinoma (Haugk 2010). Non-invasive IPMNs and MCNs
have an excellent prognosis; surgical intervention is considered curative.
National  and  international  guidelines  direct  the  follow-up  and  treatment  of
the cystic neoplasms of the pancreas (Tanaka 2012, Del Chiaro 2013).
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6.4.2 Accumulation of gene mutations
The molecular biology of pancreatic cancer continues to offer challenges due
to  the  complexity  and  heterogeneity  of  its  genetic  basis.  Accumulation  of
successive  gene  mutations  seems  to  be  the  preliminary  step  for  PDAC
development. For example, one genetic analysis of 456 PDAC specimens
revealed 32 recurrently mutated genes that could be organized into ten main
tumorigenic pathways (Bailey 2016).
Almost  all  fully  established  PDACs  contain  at  least  one  of  the  four  most
common genetic  alterations.  Over  90% include  a  mutation  of  the  oncogene
KRAS,  which  leads  to  increased  proliferation,  cell  survival,  and  suppressed
apoptosis (Almoguera 1988, Hruban 1993, Ferro 2014). KRAS mutations are
common  also  in  early  precursor  lesions.  Likewise,  80  to  95%  of  pancreatic
malignancies  carry  an  inactivation  of  the  CDKN2A  tumor  suppressor  gene,
leading to the loss of cell-cycle regulator protein p16, followed by an increase
in  cell  proliferation  (Caldas  1994,  Schutte  1997).  Inactivation  of  CDKN2A
typically occurs later in the evolution of precursor lesions than does abnormal
KRAS  activation,  with  increasingly  higher  frequencies  according  to  the
progressing PanIN grades (Gnoni 2013). Other frequently mutated tumor-
suppressor genes found in pancreatic malignancies include TP53 (inactivated
in 50-75% of the cases), a gene critical in apoptotic signaling and control of
DNA damage during the cell cycle (Redston 1994). The fourth most commonly
mutated gene is SMAD4 (inactivated in about 55% of the cases), an important
regulator of the transforming growth factor-β (TGF-β) signaling pathway
(Wilentz 2000). Considerably rarer mutations include BRCA2 and STK11 and
other defects associated with hereditary cancer syndromes (Table 2).
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6.4.3 Inflammation and stromal elements
In  the  early  1990’s,  studies  revealed  that  chronic  inflammation,  such  as  in
chronic  pancreatitis,  amplifies  the  risk  for  cancer  (Ekbom  1993,  Lowenfels
1993, Coussens 2002, Whitcomb 2002, Raimondi 2010). Activation of the
immune  system  occurs  in  response  to  injury  when  pancreatic  acinar  cells
release  inflammatory  signals  such  as  interleukin  (IL)  6,  IL-1b,  and  tumor
necrosis  factor  (TNF)  α.  Initially,  activated  immune  cells  eliminate  those
pancreatic cells that have genetic alterations, but over time, the anticancer
response becomes insufficient. In the process, pancreatic stellate cells start
producing large amounts of  ECM compounds,  and more inflammatory cells
invade.  Slowly,  a  tumor is  established,  and its  microenvironment,  abundant
with tumor-associated macrophages (TAMs), neutrophils, and CD (cluster of
differentiation) 4+ T-cells, is highly immunosuppressive, allowing the tumor
to grow and begin invasion (Neesse 2015). Furthermore, tumors themselves
cause inflammation and can instigate a cancer-related systemic inflammatory
response (SIR) (Atsumi 2014). Cancer-related SIR may be a mediator of some
cancer-associated symptoms such as weight-loss, fatigue, pain, fever, and
depression, ones resulting from circulating inflammatory cytokines such as IL-
6 and TNFα (Bower 2013, Laird 2013).
Pancreatic cancer is characteristically hypovascular and is extremely stroma-
rich,  being  composed  of  almost  90%  extracellular  matrix  (ECM),  with  a
complex assembly of fibroblasts, immune and neural cells, pancreatic stellate
cells,  blood  vessels,  and  a  vast  collection  of  growth  factors,  adhesion
molecules, and structural compounds such as collagens, fibronectin, and
hyaluronic acid (Feig 2012) (Figure 3). Cancer cells and tumor-stroma cells
promote secretion of the structural compounds of the ECM by activating
multiple signaling pathways such as TGF-β, fibroblast growth factor (FGF),
insulin-like growth factor 1 (IGF-1), hepatocyte growth factor (HGF-Met), and
epidermal growth factor (EGF) (Neesse 2011).  The tumor ECM is continuously
remodeled  by  proteinases  such  as  ADAMs  (a  disintegrin  and  a
metalloproteinase) and MMPs (matrix metalloproteinase), these counteracted
by tissue inhibitors of metalloproteinases (TIMPs), among others, all of which
are  important  mediators  in  tumor-cell  invasion.  Members  of  the  ADAM,
MMP, and TIMP families are upregulated in pancreatic cancer and have been
implicated in the invasion-metastasis cascade (Lunardi 2014, Sahin 2016).
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Figure 3. Components of Pancreatic Cancer. Pancreatic cancer comprises several
interactive elements such as pancreatic-cancer cells, cancer stem cells, and the
dense tumor stroma. This complex system involves multiple activated pathways as
well as numerous secreted cytokines and growth factors. Figure reproduced with
permission from Hidalgo, M. 2010, "Pancreatic cancer", New England Journal of
Medicine, vol. 362, no. 17, pp. 1605-1617. Copyright Massachusetts Medical Society.
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Although genetically altered cancerous pancreatic cells are the preliminary
step in tumor development,  the cancer stroma participates actively in many
tumor-sustaining actions (Figure 4).  Cancer cells  are able to recruit  normal
cells  to  serve  the  cancer  cells'  own  advantage  (Hanahan  2012).  Pancreatic
cancers contain immunosuppressive infiltrating immune cells even in the
absence of an inflammatory immune response, and these cells are present also
in the early PanIN lesions. Oncogenic activation of KRAS in pancreatic cells
leads to the transcription of granulocyte-macrophage colony-stimulating
factor (GM-CSF) that promotes the recruitment of myeloid progenitor cells
(Neesse  2015).  Mutations  of  KRAS  and  inflammation  also  promote  the
recruitment of infiltrating CD4+ T lymphocytes, which, in turn, participate in
PanIN formation by blocking the CD8+ T cell-mediated anticancer immune
responses (McAllister 2014).
In  response  to  the  signaling  by  cancer  cells  and  infiltrating  immune  cells,
cancer-associated fibroblasts start abundantly secreting the structural
compounds  of  the  tumor  stroma,  probably  reflecting  distorted  tissue-repair
mechanisms (Hanahan 2012). In the tumor microenvironment, cancer-
associated  fibroblasts  also  play  an  immunosuppressive  role  by  their
interaction  with  T  lymphocytes  (Feig  2013).  The  stromal  cells  are  active
producers of, for example, pro-angiogenic and tumorigenic growth factors,
they participate in the epithelial-to-mesenchymal transition of cancer cells,
and thus participate in initiation of the invasion-metastasis cascade (Hanahan
2012, Chaffer 2011).
Pancreatic stellate cells are pancreas-specific myofibroblasts that functionally
and  morphologically  resemble  hepatic  stellate  cells.  Abundant  in  chronic
pancreatitis, they are the main producers of the ECM in PDAC (Bachem 1998).
In surgically treated PDAC, high activity of pancreatic stellate cells correlates
with worse prognosis (Erkan 2008).
The excessive stroma of PDAC functions also as a biophysical barrier to drug
delivery  and  therefore  is  a  mediator  of  PDAC’s  characteristically  high
resistance to cancer chemotherapy. The continuous production of ECM raises
the interstitial pressure, which compresses the capillaries and hinders blood
perfusion, leading to hypoxia and decreased accessibility by anti-tumor agents
(Heinemann 2014). The central role of the tumor microenvironment makes it
a  relevant  focus  for  novel  therapy  targets.  Possible  therapies  could  prove
effective not only by directly targeting the stromal cells but also by breaking
down the structural compounds of the ECM, by relieving vessel compression
(thus  increasing  drug  delivery  into  the  tumor),  and  by  enhancing  drug
accumulation within the tumor (Neesse 2013).
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Figure 4. Contributions of some activated stromal cells to progression of
cancer. The figure illustrates the central roles of infiltrating immune cells, cancer-
associated fibroblasts, and vascular cells in the hallmarks of cancer, necessary for
tumor development and advancement. Figure reprinted from Cancer Cell, Vol 21,
Douglas Hanahan, Lisa M. Coussens, Accessories to the Crime: Functions of Cells
Recruited to the Tumor Microenvironment, Pages 309-322, Copyright 2012, with
permission from Elsevier.
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6.5 Diagnosis
6.5.1 Clinical presentation
The symptoms of pancreatic cancer depend on the location and the stage of
the disease but, unfortunately, often develop only at late stages. Especially in
the early course of the disease, symptoms are often vague and non-specific,
such  as  weight  loss,  upper  abdominal  discomfort,  and  nausea.  Tumors  that
develop  in  the  head  of  the  pancreas  (60-70%  of  the  cases)  can  cause
obstructive cholestasis,  indicated by painless jaundice that  can lead to early
disease-detection. Abdominal pain is more common in later stages, as well as
back pain that appears when the cancer infiltrates the retroperitoneal space.
Type  II  diabetes  mellitus  (present  in  at  least  half  the  patients)  and
malabsorption can also be manifestations reflecting functional aberrations of
the  endocrine  and  exocrine  pancreas.  Pancreatic  tumors  can  obstruct  the
pancreatic  duct,  which  may  lead  to  pancreatitis.  Less  frequently,  even
duodenal obstruction and gastrointestinal bleeding can occur. Advanced
stages often display systemic manifestations such as cachexia, venous
thrombosis, and depression (Hidalgo 2010, Ryan 2014).
Clinical examination may reveal upper-abdominal resistance, jaundice
(typically first detectable in the sclera), lymphadenopathy, hepatomegaly,
painlessly enlarged gallbladder, and ascites. Distant metastases develop
primarily  in  the  liver,  abdomen,  and  lungs.  Abnormalities  in  routine  blood
tests may include hyperglycemia, anemia, hypoalbuminemia, abnormalities in
liver-function tests, and variations in inflammatory biomarkers (Jamieson
2005, Hidalgo 2010).
6.5.2 Imaging
Often most practical for the initial examination of diffuse upper abdominal
symptoms or suspected pancreatic tumors is abdominal ultrasound, since it is
safe, readily available, and cost-effective, but its sensitivity and specificity are
deficient.  Further  evaluation  of  the  diagnosis,  staging,  and  assessment  of
resectability requires a supplemented examination. Multiphase helical
computed tomography (CT) with intravenous contrast material, endoscopic
ultrasound  (EUS)  with  biopsy,  aspiration  cytology  or  both,  and  magnetic
resonance imaging (MRI) combined with magnetic resonance
cholangiopancreatography (MRCP) provide the highest sensitivity and
diagnostic  value  (Seufferlein  2012).  Contrast-enhanced  CT  is  in  general
sufficient to frame an initial management plan for pancreatic lesions and
predicts  surgical  resectability  with  an  accuracy  up  to  80  to  90%
Review of the literature
28
(Karmazanovsky 2005) (Figure 5). EUS is useful especially to characterize
ambiguous pancreatic lesions and when pancreatic cancer is suspected, but
with no detectable mass on CT, or when pathologic confirmation is required
(De Angelis 2013). In the differential diagnosis of chronic pancreatitis and
pancreatic cancer, positron emission tomography (PET) scanning is useful but
not superior to other imaging techniques (Kauhanen 2009, Rijkers 2014). It
can be applicable for differentiating between benign and malignant pancreatic
cysts and for identifying distant metastases in selected cases (Murakami 2011,
Kauhanen 2015). Methods such as novel pancreatic-juice biomarkers,
molecular-imaging techniques, further enhancements in EUS techniques, and
combinations of these, are anticipated in future to revolutionize the detection
of early pancreatic cancer (Kenner 2015).
Figure 5. Contrast-enhanced computed tomography (CT) image of a pancreatic
tumor. A CT scan typically allows initial estimation of diagnosis, resectability, and
prognosis. The pancreatic tumor of 1.76 cm in diameter (I) is indicated by A.
29
6.5.3 Histological verification
For patients who will undergo surgery for a pancreatic tumor with suspicion
of malignancy cytological or histological verification is recommended but not
mandatory.  Instead,  histological  proof  of  malignancy  is  required  prior  to
initiation of chemotherapy or radiation therapy. If imaging techniques give
equivocal  results,  biopsy can also be a necessary approach.  In patients with
jaundice, endoscopic retrograde cholangiopancreatography (ERCP) and bile-
duct  stenting  accompanied  by  ductal  brushing  and  lavage  is  useful  when
relieving bile-duct obstruction. ERCP may provide additional information on
the bile- and pancreatic ducts. Otherwise, if no biliary obstruction is present,
endoscopic- or transabdominal-ultrasound-guided biopsies are feasible
methods to obtain a histological sample of the tumor (Ducreux 2015).
6.5.4 Tumor markers
Tumor markers are detectable biomarkers produced either by non-cancerous
cells in response to cancer, or by cancer cells themselves. They are sometimes
elevated  also  in  other  conditions,  and  most  are  produced  in  small  amounts
even in normal cells. Tumor markers in general must be easily determinable,
for  example  from  blood  samples,  body  fluids,  or  tissue  samples.  In  PDAC,
tumor markers are analyzed at diagnosis, but are neither sufficiently sensitive
nor specific to diagnose pancreatic cancer without other diagnostic methods.
They predominantly serve in the follow-up of pancreatic cancer to detect
recurrence  or  progression  of  the  disease,  but  they  can  prove  useful  in
differential diagnostics, with certain limitations.
In Finland, serum carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic
antigen (CEA) are the tumor markers routinely used in diagnosis, follow-up,
and even in the estimation of PDAC prognosis, even though their use presents
some challenges (Lundin 1994). Of these two, CA19-9 is the more specific and
sensitive for PDAC (Humphris 2012). CA19-9 (also known as sialylated Lewis-
A-antigen) is an antibody that binds to tumor surface-marker sialyl Lewis A
(Magnani  2004).  About  4  to  10%  of  Caucasian  population  are  Lewis  A-
negative  and  express  no  CA19-9,  thus,  a  negative  CA19-9  never  rules  out
pancreatic  cancer.  Its  sensitivity  for  pancreatic  cancer  is  70  to  90% and its
specificity 68 to 91% (Goonetilleke 2007). CA19-9 may also be highly increased
in other gastrointestinal tract cancers and in other adenocarcinomas, and can
be  due  to  non-malignant  conditions  such  as  pancreatitis,  cholangitis,  liver
cirrhosis, decompensated DM, and biliary obstruction. Further, it is relatively
insensitive regarding early, small-diameter, and poorly differentiated PDACs
(Duffy  2010).  Although  CA19-9  fails  to  meet  the  criteria  for  a  diagnostic
marker, it nevertheless proves a useful tool for PDAC assessment: prominently
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increased pretreatment CA19-9 levels >100 kU/L may predict unresectable or
metastatic disease, a decrease in post-treatment CA19-9 serum level is
associated with prolonged survival, and its fluctuations can indicate
responsiveness to chemotherapy (Ballehaninna 2012).
CEA is commonly used in diagnosis of colorectal cancer, but it can be likewise
elevated in gastric and pancreatic cancers. Additionally, smoking, banana
consumption, and nonspecific colitis can elevate CEA. In pancreatic cancer, its
sensitivity in a recent pooled meta-analysis  was 40% and its  specificity  81%
(Zhang 2015). Other serum markers for diagnosis of pancreatic cancer include
CA125, CA242, HCG-β, tissue polypeptide antigen (TPA), macrophage
inhibitory cytokine-1 (Mic-1), and insulin-like growth-factor binding protein-
1  (IGFBP-1),  among  others,  but  none  of  these  is  yet  in  routine  clinical  use
(Louhimo 2004, Duffy 2010, Coppin 2016). Combining several of these tumor
markers enhances diagnostic specificity but reduces its sensitivity.
Although tissue tumor-markers are targets of strenuous exploration in the
search for an appropriate diagnostic tool for early PDAC, unfortunately, efforts
have  as  yet  been  unsuccessful.  For  example,  KRAS and  p53  mutations  lack
sensitivity and specificity, because either can occur in pancreatitis and in
precursor  lesions;  some  mucins  and  micro-RNAs  have  been  slightly  more
promising. Cytokines, especially in panels combined with CA19-9, seem to be
of  some diagnostic  value but evidence is  still  insufficient (Yako 2016).  Thus
far, the European Group on Tumor Markers status report states that the gold-
standard tumor marker for patients with PDAC remains CA19-9 (Duffy 2010).
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6.6 Treatment of pancreatic cancer
6.6.1 Staging and treatment strategy
Treating patients with pancreatic cancer requires a multidisciplinary team
including oncologists, surgeons, radiologists, pathologists, anesthesiologists,
gastroenterologists,  dietitians,  social  workers,  and experts  on palliative care
(Pawlik  2008).  To  evaluate  PDAC  resectability,  it  is  staged  based  on  CT
imaging according to tumor-node-metastasis (TNM) classification. The
American Joint Committee on Cancer (AJCC) has established a staging system
in  which  stages  I  and  II  are  considered  resectable  and  stages  III  and  IV
unresectable (Table 3).
For patients with local stage I and II resectable pancreatic cancer, surgery is
the treatment of choice, if the patient is otherwise fit for that large an operation
(Carpelan-Holmstrom  2005,  Shaib  2007).  Even  in  the  elderly,  age  alone
should not be contraindicative for pancreatic resection (Riall 2009).
Centralization of pancreatic surgeries into high-volume hospitals is beneficial
to patient outcome with fewer complications and lower mortality rates
(Nordback 2002, Gooiker 2011, de Wilde 2012, Mamidanna 2016).
Table 3. Staging of pancreatic cancer.
Tumor Nodal Distant
Grade Status Metastases
IA T1 N0 M0
IB T2 N0 M0
IIB T1-3 N1 M0
IV T1-4 N0/N1 M1
III T4 N0/N1 M0
Stage
IIA T3 N0 M0
Characteristics
Tumor limited to the pancreas,  ?2 cm in longest dimension
Tumor limited to the pancreas,  >2 cm in longest dimension
Regional lymph-node metastasis
Tumor extends beyond the pancreas but does not involve the celiac
axis or superior mesenteric artery
Tumor involves the celiac axis or the superior mesenteric artery, no
distant metastasis (unresectable disease)
Distant metsastasis
Reproduced with modifications with permission from Hidalgo, M. 2010, "Pancreatic cancer", New England
Journal of Medicine , vol. 362, no. 17, pp. 1605-1617. Copyright Massachusetts Medical Society.
N denotes regional lymph nodes, M distant metastases, and T primary tumor.
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The International Study Group of Pancreatic Surgery (ISGPS) defines
borderline resectable pancreatic cancer in their consensus statement
according to the National Comprehensive Cancer Network’s (NCCN) previous
recommendations (Bockhorn 2014, National Comprehensive Cancer
Network) (Table 4). Generally, in locally advanced pancreatic cancer, venous
resections should not be considered contraindicative if the patient is otherwise
suitable for pancreatic surgery. In contrast, arterial resection must be
considered  more  individually;  it  may  be  justifiable  in  selected  cases,  but
predominantly, patients with arterial infiltration should be initially treated
with neoadjuvant therapy and afterwards be reevaluated (Seufferlein 2012,
Bockhorn 2014).
Following the CT, with a pancreatic-tumor protocol and initial evaluation of
resectability, several factors still remain for consideration. Approximately 70%
of  all  patients  with  pancreatic  cancer  develop  jaundice  due  to  biliary
obstruction  which  can  be  relieved  by  endoscopic  stenting  via  ERCP,  during
Localized and resectable Borderline resectable Unresectable?
No distant metastasis No distant metastasis Distant metastasis
No radiographic evidence of
SMV or PV distortion
Venous involvement of the SMV
or PV with distortion or
narrowing of the vein or
occlusion of the vein with
suitable vessel proximal and
distal, allowing for safe
resection and replacement.
Greater than 180° SMA
encasement, any celiac
abutment, IVC
Clear fat planes around CA,
HA, and SMA
GA encasement up to the
hepatic artery with either short
segment encasement or direct
abutment of the HA without
extension to the CA
Unreconstructible SMV/portal
occlusion
Tumor abutment of the SMA not
to exceed 180° of the
circumference of the vessel
wall.
Aortic invasion or encasement
Table reprinted from Surgery , Vol. 155, no. 6, Maximilian Bockhorn, Faik G. Uzunoglu,
Mustapha Adham, et al. Borderline resectable pancreatic cancer: A consensus statement by the
International Study Group of Pancreatic Surgery (ISGPS), Pages 977-988. Copyright (2014),
with permission from Elsevier.?
Table 4. Definition of resectability status according to NCCN version 1.2013 guidelines.
Abbreviations: CA, Celiac axis; GA, gastroduodenal artery; HA, hepatic artery; IVC, inferior vena
cava; NCCN, National Comprehensive Cancer Network; PV, portal vein; SMA, superior mesenteric
artery; SMV, superior mesenteric vein
*Criteria are given only for carcinomas of the head.
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which it is also recommendable to take a cytology sample. Preoperative biliary
decompression is not routinely advisable if it delays surgery in resectable
pancreatic cancer, unless the patient has cholangitis or needs other
preoperative evaluation or treatment delaying surgery (van der Gaag 2010,
Fang 2012). In locally advanced and metastatic disease (unresectable), ERCP
is recommended if otherwise possible, but this can be limited by comorbidity
(Boulay 2014). Even though a pancreatic tumor is staged as resectable by the
imaging techniques, guidelines still encourage staging laparoscopy to avoid
unnecessary laparotomy, especially in large tumors and in cases with high
CA19-9, because distant metastases are discovered during surgery in 10 to 20%
(Seufferlein 2012, Allen 2013, Schnelldorfer 2014).
Patients with technically unresectable or borderline resectable pancreatic
cancer may benefit from an attempt to downsize the tumor with neoadjuvant
chemotherapy or chemoradiotherapy (Gillen 2010). When successful,
neoadjuvant therapy converts the tumor to resectable. In contrast, no patient
whose  cancer  progresses  during  neoadjuvant  treatment  is  a  candidate  for
surgery (Callery 2009, Seufferlein 2012). Metastatic pancreatic cancer is
always considered unresectable and incurable, although selected cases receive
palliative  surgery.  In  unresectable  disease,  the  aim  of  any  treatment  is
extension of survival and palliation of symptoms.
6.6.2 Pancreatic surgery
Radical surgery in combination with oncological treatment remains the only
PDAC cure.  Only approximately 10 to 20% of  the patients are,  at  diagnosis,
candidates for surgical treatment (Seppänen 2016, Siegel 2016). Surgery
extends the median survival time of such patients from 6 months (all stages at
diagnosis)  to  11  to  24  months  (Hidalgo  2010,  Vincent  2011).  The  5-year
survival  of  surgically  treated  pancreatic  cancer  ranges  from  7  to  25%
(Seppänen  2016,  Cancer  Research  UK).  Although  pancreatic  surgery  is
invasive and demanding, perioperative mortality is relatively low, especially in
high-volume centers, ranging from 1 to 4% (Hartwig 2016, Mamidanna 2016,
Seppänen 2016). The major aim of the operation is total removal of the tumor
with  radical  (R0)  ≥1  mm  margins;  this  is  achievable  in  26  to  74%
(Chandrasegaram 2015).
The  majority  of  pancreatic  tumors  localize  in  the  head  of  the  pancreas,  in
which  case  the  surgery  is  generally  pancreaticoduodenectomy  either  by  a
pylorus-preserving or standard procedure (Whipple 1935) (Figure 6). Distal
(left) pancreatic resection including splenectomy, is often feasible approach if
the tumor is situated in the pancreatic body or tail, although these sometimes
require total pancreatectomy (Tol 2014).
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Figure 6. A) Standard (Whipple) pancreaticoduodenectomy and B) situation
after reconstruction.  1 = tumor in the head of the pancreas; 2 = head of the
pancreas; 3 = body of the pancreas; 4 = tail of the pancreas 5 = bile duct
(hepatocholedochus); 6 = gall bladder; 7 = stomach; 8 = duodenum; 9 = jejunum.
Illustration by the author.
According to the ISGPS consensus statement in 2014, the standard
lymphadenectomy during pancreaticoduodenectomy comprises the lymph
nodes in the anterosuperior group along the common hepatic artery, along the
bile- and the cystic duct, the posterior and anterior groups of the head of the
pancreas, and those along the right lateral superior mesenteric artery, as well
as the suprapyloric and infrapyloric lymph nodes (Tol 2014). Furthermore, the
lymphadenectomy  should  include  ≥15  lymph  nodes,  and  the  pathologist
should report the lymph-node ratio (LNR, metastatic lymph nodes divided by
total number of lymph nodes examined) in the analysis. Neither extended
lymphadenectomy, pylorus preservation, more extensive surgery, nor
minimally invasive techniques seem to provide any survival benefit (Hartwig
2013, Ryan 2014, Dasari 2015, Ricci 2015). Unfortunately, after surgical
resection, patients often develop systemic (>70%) and local recurrence
(>20%)  (Hidalgo  2010).  Yet,  due  to  improved  oncological  treatment,
reoperation after PDAC recurrence and even resection of treatment-
responding metastases may in a few carefully selected cases improve patient
outcome (Miyazaki 2014, Chang 2016, Crippa 2016).
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6.6.3 Oncological treatment
Oncological treatment includes chemotherapy and radiotherapy administered
pre-  or  post-operatively  or  in  advanced  disease.  The  aim  of  neoadjuvant
therapy, administered prior to surgery, is to convert primarily unresectable
disease to resectable by tumor downsizing.  Post-operational adjuvant therapy
reduces  risk  for  recurrence  and  improves  patient  outcome.   The  aim  of
palliative therapy is to prolong life expectancy in metastatic and unresectable
disease. However, high resistance to systemic therapies is characteristic of
PDAC,  and  chemotherapy  alone  cannot  be  expected  to  be  curative  (Ryan
2014).
5.6.3.1 Neoadjuvant therapy
Neoadjuvant  therapy  with  gemcitabine  (sometimes  in  combination  with
another cytostatic) or FOLFIRINOX (a chemotherapy regimen combining
folinic  acid,  fluorouracil,  irinotecan,  and  oxaliplatin),  followed  by
chemoradiation  if  suitable,  is  considered  if  the  tumor  is  local  but  primarily
borderline resectable or unresectable (Ducreux 2015). A good response to
neoadjuvant treatment converts the tumor to resectable in some 30 to 60% of
cases and improves the outcome of patients with borderline resectable PDAC
so it becomes close to the outcome of patients with primarily resectable disease
(Gillen  2010,  Assifi  2011,  Andriulli  2012).  According  to  a  meta-analysis  in
2010,  survival  of  patients with resectable pancreatic  cancer is  unaffected by
neoadjuvant  therapy;  it  should  be  the  choise  only  for  primarily  borderline
resectable disease (Gillen 2010). Currently, several randomized multi-center
studies are prospectively assessing potential neoadjuvant treatment regimens
(Ducreux 2015, Shaib 2016).
5.6.3.2 Adjuvant therapy
The current recommendation for all patients undergoing surgery for PDAC is
6 months (including six cycles) of postoperative adjuvant chemotherapy with
either gemcitabine or 5-fluorouracil (5-FU), beginning approximately 12
weeks after surgery (Neoptolemos 2010, Liao 2013, Oettle 2013, Valle 2014).
Adjuvant therapy improves both disease-free survival and overall survival with
gemcitabine and 5-FU equally. Adjuvant chemoradiotherapy, frequently used
in the USA but rarely in Europe, plays a more controversial role, and its benefit
is still under debate (Neoptolemos 2001, Liao 2013, Neuzillet 2015).
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5.6.3.3 Palliative therapy
For advanced PDAC, the only validated treatment until 2010 was gemcitabine,
but  PDAC  is  highly  resistant  to  chemotherapy;  only  approximately  15%
respond to gemcitabine in advanced disease (Hashimoto 2009).  Furthermore,
gemcitabine improves median survival time of advanced PDAC rather
modestly, from 3 months (with the optimal supportive care) to 5 to 6 months.
Recent data indicate that the expression of a membrane transporter, human
equilibrative nucleoside transporter 1 (hENT1), is associated with
responsiveness  to  gemcitabine  and  also  with  overall  survival;  it  could
potentially prove useful in prognostic evaluation (Nordh 2014).
Combining nab-paclitaxel with gemcitabine improves median survival time to
8.5  months  (Von  Hoff  2013),  and  the  combination  regimen  FOLFIRINOX
extends median survival time to 11.1 months (Conroy 2011). The disadvantage
of combination therapies is their higher toxicity, so only those patients with
good performance status are eligible. Single-gemcitabine remains the
treatment  of  choice  for  patients  >75  years  of  age  or  with  moderate
performance status. Currently, the combination therapies undergo study also
in neoadjuvant and adjuvant settings (Neuzillet 2015).
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6.7 Prognostic evaluation
6.7.1 Patient-related prognostic factors
The incidence of pancreatic cancer increases progressively with age. In most
studies, the prognosis is unaffected by age alone, although increasing age often
brings  more  co-morbidities,  which,  in  turn,  can  affect  survival  (Riall  2009,
Casadei  2014,  Teague  2015).  Pancreatic  cancer  is  slightly  more  common  in
men  than  women,  but  few  studies  concern  gender’s  association  with
prognosis;  the  few  that  exist  show  no  significant  correlation  (Molife  2001).
Simultaneous  diabetes  mellitus  (mainly  type  2),  being  common  in  patients
with pancreatic cancer, seems to be associated with worse survival, especially
in surgically treated patients (Li 2012, Toriola 2014).
6.7.2 Tumor-related prognostic factors
In pancreatic cancer, the key determinants of prognosis are tumor stage and
resectability (Table 3). If the tumor is unresectable, the disease is incurable,
and  expected  survival  time  is  only  a  few  months,  increased  marginally  by
chemotherapy.
Once the tumor is resected, several prognostic factors can be determined from
the resected preparate. One of the critical factors is radicality of the resection:
an >1 mm resection margin of  tissue without tumor infiltration (R0).  Other
well-established prognostic factors include tumor size, tumor differentiation
grade, lymph-node metastasis (N0/N1), as well as neural, lymph-vessel and
vascular tumor invasion (Gebhardt 2000, Garcea 2008, Benassai 2015).
Further, lymph-node involvement alone is not as important in the prognosis
as is the LNR; a high LNR (number of metastatic lymph nodes divided by total
number of lymph nodes analyzed >0.2) is an important independent negative
prognostic factor (Riediger 2009, Huebner 2012, Robinson 2012, Valsangkar
2013).
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6.7.3 Prognostic serum tumor markers and tissue markers
Several biomarkers detectable either in the peripheral blood circulation or in
the  tumor  mass  correlate  with  PDAC  prognosis.  Serum  tumor  markers  of
PDAC, including CA19-9, CEA, CA242, and CA72-2, have prognostic potential
particularly  in  advanced  disease  based  on  their  dynamics  in  response  to
chemotherapy (Louhimo 2004, Boeck 2006, Goonetilleke 2007, Ballehaninna
2012, Humphris 2012, Liu 2015, Reitz 2015). CA19-9 and CEA predict
prognosis also in resectable PDAC, and an increase in CA19-9 or CEA levels
after treatment is indicative of disease recurrence and progression (Lundin
1994, Distler 2013, Piagnerelli 2016). Moreover, many tissue markers show
prognostic potential, including PROX1, beta-catenin, podocalyxin (Saukkonen
2015, 2016), the cytoskeletal protein ezrin (Piao 2015), several members of the
MMP family (Juuti 2006, Mroczko 2009, Xu 2015), and some growth factors
(Yamanaka 1993, Uegaki 1997).
6.7.4 Prognostic potential of inflammatory biomarkers
Tumor-associated inflammation can lead to elevated concentrations of
inflammatory  biomarkers  in  the  peripheral  blood  circulation.  Levels  of  C-
reactive protein (CRP) above normal are associated with worse prognosis in
cancers of the breast, colon, and urological system (Han 2011, Kersten 2013,
Saito 2013, Thurner 2015). A correlation between CRP and PDAC prognosis is
best established in patients receiving palliative chemotherapy (Haas 2013,
Mitsunaga 2016). In patients operated on with curative intent, study cohorts
have been very small. A meta-analysis in 2015 noted that elevated CRP level
may  be  independently  indicative  of  worse  prognosis  in  PDAC,  but  further
studies are necessary (Stevens 2015).
The  most  abundant  protein  in  the  human  blood  circulation  is  albumin
(Farrugia 2010); its reduced levels (hypoalbuminemia) indicate poor
nutritional status, but are also related to SIR (Gabay 1999). Hypoalbuminemia
is associated with poor clinical outcomes in acute illnesses (Vincent 2003) and
in  some  cancer  forms  (McMillan  2001,  Ataseven  2015,  Chiang  2015,  Kim
2015).  In  resectable  PDAC,  the  effect  of  hypoalbuminemia  on  prognosis  is
controversial (Ruiz-Tovar 2010, La Torre 2012, Stotz 2013). Combinations of
different inflammatory markers have been created to estimate cancer
prognosis. Recent international guidelines recommend measurement of either
the modified Glasgow prognostic score (mGPS) or the neutrophil-to-
lymphocyte  ratio  (NLR)  in  all  patients  considered  for  resection  of  PDAC
(Bockhorn 2014).
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5.7.4.1 The Glasgow prognostic score
A  combination  of  elevated  CRP  and  low  albumin  levels,  the  Glasgow
prognostic  score (GPS),  was originally  designed in a cohort  of  patients with
non-small-cell lung cancer for estimating their prognosis (Forrest 2003).
Later, McMillan et al. (2007) modified the GPS by emphasizing the elevated
CRP, because, in some studies, hypoalbuminemia was not an independent
predictor  of  survival.  In  one  large  retrospective  cohort  study,  the  modified
Glasgow prognostic score (mGPS) predicted cancer survival independent of
tumor  site  (Proctor  2011).  Table  5  shows  how  the  GPS  and  the  mGPS  are
determined (Proctor 2011, Forrest 2003).
5.7.4.2 Prognostic ratios based on inflammatory cells
Some inflammatory-cell-based ratios also predict cancer-patient survival.
Elevated NLR has lately been recognized in several cancer forms as a simple
indicator of worse prognosis (Li 2014, Paramanathan 2014, Xiao 2014, Zhang
2014, Yang 2015). NLR is, according to some recent studies, feasible also in
resectable pancreatic cancer to predict postoperative survival (Stotz 2013,
Stevens  2015).  Furthermore,  the  platelet  to  lymphocyte  ratio  (PLR)  shows
some prognostic potential in malignancies including PDAC (Koh 2015, Shirai
2015, Spolverato 2015), but in significance PLR loses out to NLR (Bhatti 2010,
Azab 2014, Zhang 2014).
Score 0 1 2
GPS Normal CRP <10 mg/L Elevated CRP >10 mg/L Elevated CRP >10 mg/L
AND OR AND
Normal albumin >35 g/L Hypoalbuminemia <35 g/L Hypoalbuminemia <35 g/L
mGPS Normal CRP <10 mg/L Elevated CRP >10 mg/L Elevated CRP >10 mg/L
AND AND
Irrespective of albumin Normal albumin >35 g/L Hypoalbuminemia <35 g/L
Table 5. The Glasgow prognostic score (GPS) and modified Glasgow prognostic score
(mGPS) calculated with C-reactive protein (CRP) and albumin.
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6.8 Macrophages and pancreatic cancer
6.8.1 Polarization of macrophages: types M1 and M2
Macrophages  are  a  type  of  white  blood  cells  found in  practically  all  human
tissues.  They  eliminate  cellular  debris,  microbes,  and  foreign  substances  by
phagocytosis,  being among the first  cells  to infiltrate a damaged or infected
tissue. They prove critical in both innate and adaptive immunity by activating
other immune cells. For decades, scientists focused on their role in immune
defense, but macrophages are additionally pivotal in immune regulation and
homeostasis  by,  for  example,  participating  in  tissue  remodeling  and  wound
healing via mechanisms independent of immune-cell signaling (Erwig 2007).
Macrophages  originate  from  common  hematopoietic  stem  cells  in  the  bone
marrow, where they differentiate first through the myeloid and then trough
the monocyte lineage.  Monocytes are mobilized from the bone marrow into
the blood stream; subsequently they extravasate and infiltrate target tissues
both  in  the  steady  state  and  also  in  response  to  inflammation.  In  tissues,
monocytes mature into tissue-specific macrophages (Gordon 2005).
Macrophages  are  remarkably  diverse  and  plastic  cells  that  respond
dynamically to environmental signaling by efficiently changing their
functional phenotype, which leads to alterations in their physiology (Mosser
2008). In the 1990s, scientists discovered that besides their classical activation
in response to interferon (IFN) γ and toll-like receptor (TLR) agonists, there
is also an alternative route to macrophage activation, detected by up-regulated
expression of the mannose receptor (CD206), enhanced by Th2 cell-produced
IL-4 and IL-13 (Stein 1992,  Doyle 1994).  The distinct  types of  macrophages
were later  named analogously to T-cell  nomenclature (Th1 and Th2),  as  M1
and M2 macrophages (Mills 2000).
The classically activated type of M1 macrophages are pro-inflammatory; they
participate actively in the host defense by being effectors of Th1 responses;
they produce high amounts of inflammatory cytokines such as IL-1β, IL-6, IL-
12,  IL-23,  and  TNFα;  and  they  mediate  resistance  against  tumors  and
microbes  (Mantovani  2005)  (Figure  7).  By  definition,  all  other  types  of
macrophages are subtypes of M2 macrophages, playing varying roles in tissue
repair, immune regulation, and even in cancer promotion. They mediate their
immune-response suppressive role by producing anti-inflammatory cytokines
such as IL-10 (Mosser 2008, Sica 2012). Type M2 macrophages can be further
divided into several subgroups called M2a, M2b, M2c, and M2d (Edwards
2006,  Mosser  2008,  Sica  2012).  Besides  the  division  of  M1  and  M2
macrophages by the inflammatory and anti-inflammatory cytokines they
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produce, there occur several patterns of cell-surface markers for macrophage
characterization. Cell-surface markers that are characteristic of M1
macrophages  include  CD80  and  CD86,  whereas  characteristic  for  M2
macrophages are CD206 (mannose receptor), CD209, and CD163 (scavenger
receptor). CD14 is expressed in most macrophages but is especially abundant
in TAMs. This division is, however, a simplification, and in reality,
macrophage polarization is much more complex; M1 and M2 macrophages are
only the two extremes of the spectrum of macrophage polarization (Mosser
2008, Sica 2013).
Due  to  their  plasticity,  macrophages  can  efficiently  change  their  M1/M2
polarization in response to environmental stimuli. Moreover, macrophages
autoregulate  themselves  by  forming  positive  feedback  loops  in  which  the
inflammatory  cytokines  produced  by  M1  and  the  anti-inflammatory  ones
produced by M2 cells further stimulate their polarization to shift towards their
respective phenotypes (Mantovani  2007). Under in vivo conditions often
simultaneously multiple opposing reprograming signals operate in
macrophage microenvironment. The fact that researchers have been able to
induce, reverse, and re-polarize macrophage activation promises important
therapeutic implications (Sica 2012, Zhou 2014).
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Figure 7. Simplified view of macrophage polarization to types M1 and M2. In the
presence of microbial and Th1 cell products such as IFN? and LPS, monocytes
differentiate preferentially into M1 macrophages that produce inflammatory mediators
and enhance the inflammatory response. IL-4 and other anti-inflammatory cytokines
skew macrophage polarization toward type M2 macrophages that in turn produce
immunoregulatory cytokines. In reality, macrophage polarization is a continuum with
both inflammatory and immunoregulatory properties. Illustration by the author.
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6.8.2 Tumor-associated macrophages
Macrophages  are  in  cancerous  tumors  a  major  stromal  component  (Feig
2012). Chemokines, cytokines, and products of the complement cascade
recruit circulating monocytes to the tumor site (Franklin 2014, Noy 2014). In
the proximity of tumor cells macrophages, differentiate into type M2d
macrophages, also referred to as tumor-associated macrophages (TAMs) (Sica
2012). In tumors, TAM abundance is correlated with immunosuppression,
tumor growth, neovascularization, invasiveness, metastasis, and resistance to
therapy  (Qian  2010).  TAMs  show  various  tumor-promoting  functions;  for
example, they support tumor vascularization by producing pro-angiogenic
factors  such  as  vascular  endothelial  growth  factors  (VEGFs).  They  also
suppress anticancer-immune responses, for example the cytotoxity of CD8+ T
cells.  Further,  TAMs  modulate  and  degrade  the  extracellular  matrix  (ECM)
through such products as secreted protein acidic and rich in cysteine (SPARC)
and MMPs aiding cancer cells to invade the blood vessels and thus metastasize
(Puolakkainen 2004, Arnold 2010, Kitamura 2015, Shen 2016).
An important signaling pathway in pancreatic cancer cells and macrophages
seems to be the STATs (signal transducers and activators of transcription), a
family of transcription factors activated by tyrosine phosphorylation of Janus-
activated  kinases  (JAKs).  Several  cytokines  and  growth  factors  can  bind  to
JAKs,  and these transfer extracellular signals  via STATs to the cell  nucleus,
where STATs bind to promoter sequences and activate gene transcription (Hu
2007). The JAK/STAT pathway is responsible for the activation of thousands
of protein-encoding genes, including those important for cell proliferation and
macrophage differentiation; it is therefore not surprising that several types of
tumors display aberrant STAT activation (Toyonaga 2003, Palagani 2014,
O'Shea 2015). In macrophages, the STAT 1 pathway is predominantly activated
in M1, but STAT 3 and 6 are activated in type M2 (Porta 2015).
During cancer progression, the TAM phenotype changes and varies even in the
tumor tissue itself. In tissues with chronic inflammation and initial cancer
development, primarily M1 macrophages occur, whereas M2 macrophages are
more abundant at later stages when the tumor begins neovascularization and
invasion (Mielgo 2013). Complex signaling from tumor- and host cells further
shape TAMs’ functional phenotypes. Cancer cells generate cytokines such as
TGFβ and Colony-Stimulating Factor-1 (CSF-1, also known as macrophage-
colony-stimulating factor, M-CSF) and metabolic products (lactic acid among
others) that polarize TAMs. Further, participating in this functional shaping
of TAMs are a hypoxic microenvironment, the Th2 cell products IL-4 and IL-
13, regulatory T-cell-produced IL-10, and immune complexes from B cells
(Sica 2012, Noy 2014).
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TAMs also orchestrate many mechanisms of resistance to chemotherapy,
mainly by misdirected tissue repair-responses, for example by recruitment of
more immunosuppressive TAMs, by skewing macrophage polarization
towards  pro-tumor  functions,  and  by  protecting  cancerous  cells  against
chemotherapy (Mantovani 2015). All this makes macrophages a tempting area
for  development  of  new  anticancer  therapies  and  encourages  scientists  to
explore macrophages further (Baay 2011, Noy 2014, Ostuni 2015).
6.8.3 Tumor-associated macrophages in pancreatic cancer
Pancreatic cancer is characteristically rich in stroma and inflammatory cells,
including  TAMs  (Feig  2012).  In  PDAC,  TAMs  play  a  critical  role  in  tumor
progression; abundance of TAMs is associated with worse prognosis and less
responsiveness to chemotherapy (Kurahara 2011, Yoshikawa 2012, Hou 2014,
Di Caro 2015). Analogous to other types of solid tumors, the tumor-promoting
effects of TAMs in PDAC include supporting tumor vascularization, degrading
the  ECM,  and  suppressing  immune  reactions  and  tumor-resistant  actions
(Mielgo  2013).  Further,  M2  TAMs  are,  at  least  in  part,  responsible  for
resistance to gemcitabine, whereas recruitment of type M1 macrophages
enhances gemcitabine efficacy (Beatty 2011, Weizman 2014). Some new data
even suggest that TAMs may mediate the pancreatic-cancer-suppressive
effects of metformin (Soranna 2012, Incio 2015).
Although macrophages are amply present also in chronic pancreatitis, they are
typically  of  type  M1;  in  pancreatic  cancer,  macrophages  are  polarized  more
towards the immune-response suppressive M2 phenotype (Mielgo 2013, Helm
2014,  Chen  2015).  High  levels  of  pro-inflammatory  cytokines  (for  example
TNFα,  IL-1β)  in  pancreatitis  recruit  monocytes  and  macrophages  to  the
pancreas, subsequently generating an inflammatory microenvironment (Sah
2012). In pancreatitis, neutralization of the acute inflammation leads to less
disease severity, and the transition of M1 to M2 is actually therefore favorable
(Perides 2011, Sah 2012). In contrast, in PDAC the M2 type in particular seems
to correlate with worse survival; therefore efforts focus on converting
macrophages  in  PDAC  tumors  to  the  anti-tumor  M1  type  (Kurahara  2011,
Mielgo 2013).
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6.8.4 In vitro polarization of macrophages
Macrophages for in vitro studies originate predominantly from either murine
bone marrow or human monocytes isolated from peripheral blood. Discovery
of an alternative macrophage activation route with IL-4 (in contrast to
classical activation with IFNγ) has generated a wave of studies on macrophage
polarization. Earlier, researchers have used granulocyte-macrophage colony-
stimulating factor (GM-CSF) to generate inflammatory M1 macrophages and
macrophage colony-stimulating factor (M-CSF, also called CFS-1) to generate
anti-inflammatory M2 macrophages (Fleetwood 2007). The cell cultures are
often supplemented with various cytokines to further stimulate the
macrophage activation. For example, IFNγ and LPS are typical choices for the
classical, inflammatory activation, whereas IL-4 and IL-13 serve as activators
for the alternative route (Stein 1992, Doyle 1994, Mills 2000).
The in vitro polarization and study of macrophages has raised some criticism.
The nomenclature and methods are diverse, and therefore not always directly
comparable. In a consensus study, Murray et al. (2014) emphasize the extreme
plasticity  of  macrophages  and  suggest  naming  the in vitro-differentiated
macrophages  according  to  the  stimulants  used,  as  compared  to  M1  or  M2
macrophages. In the in vitro setting, monocytes are first isolated and then
differentiated separate from their natural surroundings without interaction
with  other  immune  cells  and  stromal  elements.  Some  scientists,  like
Nahrendorf et al. (2016),  suggest  abandoning  the  M1/M2  distinction
altogether  to  avoid  an  oversimplified  view,  and  recommend  thinking  of
macrophages as a network of immune cells and referring to them according to
their function in their natural habitat.
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7 AIMS OF THE PRESENT STUDY
The main objective of this study was to create further insights into the nature
of pancreatic cancer and its association with inflammation, with emphasis on
the  role  of  tumor-associated  macrophages  (TAMs).  We  explored  the
association between TAMs and the migration of  pancreatic  cancer cells  and
the  changes  that  occur  in  macrophages  under  the  influence  of  pancreatic
cancer cells. More specifically the aims were to:
1. study the role of MMP9, ADAM8, and hypoxia in pancreatic cancer cell
invasion in co-cultures with macrophages
2. polarize macrophages into types M1 and M2 and assess their impact on
pancreatic cancer cell migration
3. investigate the possibilities of modifying pancreatic cancer cell
migration through macrophage polarization
4. assess the role of STAT activation in pancreatic cancer cell invasion in
co-cultures with macrophages
5. study the association of systemic inflammatory response with the
adverse effect on the prognosis of patients with surgically treated
pancreatic cancer
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8 MATERIALS, PATIENTS, AND METHODS
8.1 Ethical statement
All studies followed the Declaration of Helsinki and had the approval of the
Helsinki University Hospital Ethics Committee. Furthermore, Study IV had
the approval of the National Supervisory Authority for Welfare and Health
(Valvira). All healthy blood donor volunteers were informed about the study
procedures.  Patients  who  prospectively  gave  blood  samples  for  Study  IV
signed  a  written  informed  consent.  The  guidelines  of  Helsinki  University
Hospital  and  National  Data  Protection  Commission  assured  the
confidentiality of healthy subjects’ names and all patient information.
8.2 Cell lines and cultures
The source of macrophages was the isolation and differentiation of monocytes
from healthy human donors’ peripheral blood samples. The blood sample from
each donor was processed and assayed separately. First, mononuclear cells
were  separated  by  density  gradient  centrifugation  with  Ficoll-Paque  Plus
(Amershamn, Uppsala, Sweden). Monocytes were further isolated by negative
paramagnetic  bead  separation  with  the  Human  Monocyte  Isolation  Kit  II
(Miltenyi Biotec, Auburn, TX, USA) according to manufacturer’s instructions
for Studies II and III. Differentiation into macrophages was initiated directly
after monocyte isolation and continued for 5 days before addition of pancreatic
cancer cells or additional stimuli or both (Figure 8).
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Figure 8. Isolation of monocytes, their differentiation into macrophages, and
preparation for assays. (Studies I-III)
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The human pancreatic adenocarcinoma cell lines MiaPaCa-2, PANC-1
(primary tumor cell lines), HPAF-II, and ASPC-1 (metastatic tumor cell lines)
came from the American Type Culture Collection (ATCC).  Those pancreatic
adenocarcinoma cells not used in the assays were cultured and handled
according to the recommendation of the distributor. Cancer cells were added
to macrophage cultures after 5 days of monocyte isolation.
For the assays, both macrophages and pancreatic adenocarcinoma cells were
cultured in Macrophage serum-free media (Macrophages-SFM, Gibco Life
Technologies,  Paisley,  UK)  supplemented  with  penicillin  (Sigma,  St.  Louis,
MO, USA) 100 mg/ml, and either GM-CSF (ImmunoTools, Oldenburg,
Germany) 10 ng/ml or M-CSF (ImmunoTools) 50 ng/ml to differentiate the
isolated  monocytes  into  mature  M1  and  M2  macrophages,  respectively.  All
cells were incubated in standard +37 ºC and 5% CO2. The additional stimuli
were added after 5 days of monocyte differentiation (Figure 8). In Table 6 are
presented all the supplements and their concentrations added to the cell
cultures.
Abbreviation Name Concentration Supplier
GM-CSF stimulating factor 10 ng/ml ImmunoTools, Oldenburg, Germany
M-CSF Macrophage colony-stimulating factor 50 ng/ml ImmunoTools
IL-6 Interleukin 6 50 ng/ml R&D Systems, Shanghai, China
IL-4 Interleukin 4 20 ng/ml R&D Systems
LPS Lipopolysaccharide 10 ng/ml Sigma, St.Louis, MO, USA
IL-12 Interleukin 12 5 ng/ml R&D Systems
IL-10 Interleukin 10 25 ng/ml R&D Systems
P6 Pyridone 6 500 nM Calbiochem, San Diego,  CA, USA
Table 6. Supplementary stimulants and inhibitors.
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8.3 Cancer cell migration studies
After 5 days of  macrophage differentiation,  the pancreatic  cancer cells  were
stained with fluorescent dye (CellTracker Green CMFDA, Invitrogen, Eugene,
OR, USA) and added to the macrophage cultures. As controls the PDAC cells
were alternatively cultured alone under otherwise identical conditions. The
supplementary stimulants (interleukins and P6) were also added at this stage.
The  cells  were  cultured  on  Matrigel  (BD  Biosciences,  San  Jose,  CA,  USA)
simulating the ECM of the tumor microenvironment in which cells can migrate
and form three-dimensional structures. The cancer cells settled for 24 hours,
and then their migration rate was recorded by imaging their movement in a
fluorescence microscope equipped with a cooled CCD camera (Sensicam, PCO,
Kelheim, Germany) with 30-min intervals for 24 hours in a humidified
temperature (+37 ºC) and CO2 (5%) -controlled chamber (OKOlab, Ottaviano,
Italy).  In  Study  I,  we  led  a  hypoxic  gas  mixture  (5% CO2,  2% O2,  N2  94%,
Woikoski,  Järvenpää,  Finland)  into  the  chamber  to  allow us  to  observe  the
migration rate in hypoxic conditions.
8.4 Flow cytometry
We used flow cytometry to detect the expression of several surface proteins
and intracellular STAT phosphorylation of macrophages and cancer cells. To
cause as little damage to the cells as possible, the cells were cultured on Nunc
UpCell dishes (Thermo Fisher Scientific, Roskilde, Denmark) which release
the cells adhered to their surfaces when the temperature of the dish is lowered
from  +37  ºC  to  room  temperature.  For  the  labeling  antibodies  for  flow
cytometry studies, see Table 7.
To study the surface expression of macrophages (Studies II and III), we first
separated them from the cancer cells by magnetic bead separation with anti-
CD 11b MicroBeads (Miltenyi Biotec). Subsequently, we labeled the separated
macrophages with selected antibodies (CD14, CD16, CD80, CD86, CD163,
CD206, CD209) (Table 7) for 20 minutes at room temperature.
In  Study  III,  we  studied  STAT  phosphorylation  as  well  as  NFkB  and  AKT
phosphorylation in both macrophages and MiaPaCa-2. After their detachment
from culture dishes, BD Phosflow Lyse/Fix Buffer (BD Biosystems, San Diego,
CA, USA) stabilized the cells at +37 ºC for 10 minutes. Consequently, BD Perm
Buffer  (BD  Biosystems)  permeabilized  the  cells  at  -20  ºC  for  30  minutes.
Finally, we added the antibodies for CD45 (a lymphocyte marker to identify
macrophages during analysis), for STAT 1, 3, 5, and 6 and for NFkB and AKT
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(Table 7) and incubated them at room temperature for 20 minutes. We verified
the  specific  signal  pathway  activation  in  macrophages  by  stimulation  with
TNFα (10 ng/ml, 10 min, for stimulation of NFkB), IL-6 (100 ng/ml, 5 min,
for stimulation of STAT 1 and 3), IL-4 (10 ng/ml, 10 min, for stimulation of
STAT 5 and 6), and LPS (100 ng/ml, 10 min, for stimulation of AKT) prior to
addition of the Lyse/Fix Buffer.
After our labeling of the cells, they were assessed on FACS Calibur (CellQuest
Pro  software;  BD  Bioscience)  flow  cytometer,  and  WinMDI  (v2.8)  software
analyzed the data. When assessing the phosphorylation data, we separated the
results of macrophages and MiaPaCa-2 cells by separating them into CD45-
positive and -negative cells.
Table 7. The labeling antibodies for flow cytometry.
Detecting Name Amount
Incubation
time Supplier
APC Control APC Mouse IgG1 ? Isotype Control 20 μL 20 min BD Pharmingen
FITC Control FITC Mouse IgG1 ? Isotype Control 20 μL 20 min BD Pharmingen
PE Control PE Mouse IgG1 ? Isotype Control 20 μL 20 min BD Pharmingen
CD14 FITCMouse Anti-Human CD14
PE Mouse Anti-Human CD14
5 μL
20 μL
20 min
20 min
BD Pharmingen
BD Pharmingen
CD16 FITC Mouse Anti-Human CD16 20 μL 20 min BD Pharmingen
CD80 PE Mouse Anti-Human CD80 20 μL 20 min BD Pharmingen
CD86 APC Mouse Anti-Human CD86 20 μL 20 min BD Pharmingen
CD163 PE Mouse Anti-Human CD163 20 μL 20 min BD Pharmingen
CD206 APC Mouse Anti-Human CD206 20 μL 20 min BD Pharmingen
CD209 PE Mouse Anti-Human CD209 20 μL 20 min BD Pharmingen
STAT1 Alexa Fluor 647 Mouse Anti-STAT1 10 μL 30 min BD Phosflow
STAT3 PE Mouse Anti-STAT3 10 μL 30 min BD Phosflow
STAT5 Alexa Fluor 647 Mouse Anti-STAT5 10 μL 30 min BD Phosflow
STAT6 Alexa Fluor 647 Mouse Anti-STAT6 10 μL 30 min BD Phosflow
NFKB Alexa Fluor 647 Mouse Anti-NFkB 10 μL 30 min BD Phosflow
AKT PE Mouse anti-AKT 10 μL 30 min BD Phosflow
CD45 FITC Mouse Anti-Human CD45 10 μL 30 min BD Pharmingen
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8.5 Detection of protein and cytokine expression and
secretion
In Study I we detected the gene expression of ADAM8, ADAM9, ADAM10,
ADAM17, MMP2, MMP9, TIMP1, and TIMP3 by real-time PCR according to
manufacturer’s instructions (TaqMan Gene Expression Assay, Thermo Fisher
Scientific). First, we sorted the cells into CD14-positive and CD11b-positive
macrophages and cancer cells using Miltenyis MACS© Column Technology
(anti-CD14 and anti-CD11b MicroBeads, Miltenyi Biotec).
Profiling  of  secreted  cytokines  in  cell  cultures  we  assessed  with  Human
Cytokine  Array  Panel  A  (ARY005,  Proteome Profiler  Arrays,  R&D Systems,
Minneapolis,  MN,  USA)  in  Study  II  and  with  infrared  Human  Q-Plex™
Custom Assay (#107749GR, Quansys Biosciences, Logan, UT, USA) in Study
III. In order to detect the small changes in the cytokine profiles, in Study II the
media were concentrated from 1.5ml by 3K filters (Amicon Ultra Centrifugal
Units, Millipore Corporation, Billerica, MA, USA). Odyssey infrared imager
(LI-COR Biosciences, Lincoln, NE, USA) imaged both assays. Odyssey
Software (LI-COR Biosciences) and Q-View™ Software (Quansys Biosciences)
analyzed the dot blots in Studies II and III, respectively.
8.6 siRNA
The  ADAM8  and  MMP9  expression  in  pancreatic  cancer  cells  was  down-
regulated by the siRNA Transfection Kit (sc-45064, Santa Cruz Biotechnology,
Santa Cruz, CA, USA) in Study I. According to the manufacturer’s instructions,
we mixed MMP9 siRNA, ADAM8 siRNA, or non-targeting negative control
duplex (sc-41406, sc-29400, sc-37007, Santa Cruz Biotechnology), and
transfection reagent (sc-29528, Santa Cruz Biotechnology) with transfection
medium (sc-36868,  Santa  Cruz  Biotechnology).  We added  10% fetal  bovine
serum  (FBS)  after  7  h,  and  incubated  the  cells  for  an  additional  48  h.
Subsequently, we replaced the transfection medium with normal PDAC cell
culture  medium  and  10%  FBS,  and  used  the  cancer  cells  in  migration
measurements.
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8.7 Western blotting
For protein analysis in Study I, macrophages and the pancreatic cancer cells
were first sorted as described above. Consequently, we homogenized the
sorted cells with lysis buffer (Roche, Mannheim, Germany), and determined
the protein concentrations of the samples by colorimetric Bradford assay. We
diluted the protein extracts in Laemmli sample buffer, incubated them for 5
min at +95 ºC, and then resolved them in 10% polyacrylamide gels in Tris–
glycine–SDS  buffer.  For  analysis,  we  transferred  the  gels  to  nitrocellulose
membranes and blocked them in Odyssey blocking buffer (927–40,000, LI-
COR  Biosciences).  As  antibodies,  we  used  rabbit  anti-ADAM8  (1:500  v/v,
AB19017, Milllipore, Temecula, CA, USA), rabbit anti-MMP9 (1:400 v/v,
10375-2-AP, Proteintech Group, Chicago, IL, USA), mouse anti-GAPDH
(1:1,000 v/v, sc-32233, Santa Cruz Biotechnology), goat anti-rabbit IgG IRDye
800 (1:15,000 v/v, 926-31220, LI-COR Biosciences), and goat anti-mouse IgG
Alexa 680 dye (1:15,000, A21058, Molecular Probes, Eugene, OR, USA).
Odyssey infrared imager (LI-COR Biosciences) scanned the protein bands on
the membranes.
8.8 Patients for Study IV
Study IV included retrospectively all the consecutive 265 patients operated on
with  curative  intent  for  pancreatic  ductal  adenocarcinoma  at  Helsinki
University Hospital from 1 January 2000 to 30 March 2013. Table 8 displays
patient characteristics. We excluded patients who died of surgery-related
complications, had metastatic spread, emergency surgery, or at the time of the
surgery  had  infection,  an  auto-immune  disease,  or  were  on  immune-
suppressive medication. Patients were treated according to national
guidelines. Data on clinico-pathological features and laboratory findings came
from  patient  records,  except  for  the  CRP,  which  was  determined  from
preoperatively (prospectively for study purposes) -collected plasma samples of
230 patients.  The samples had been stored in freezers at  -80 ºC.  Minimum
follow-up time was 2 years, with the end of follow-up on 30 March 2015. Study
IV applied the Reporting Recommendations for Tumour Marker Prognostic
Studies (REMARK) (Altman 2012).
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Median survival
Total n=265 n (%) time (95% CI) p (survival time)
Sex 0.453
Male 150 (56.6) 25.4 (18.9-31.9)
Female 115 (43.4) 26.9 (23.8-30.0)
Age (years) 0.177
<60 70 (26.4) 27.4 (19.8-35.0)
60-64 57 (21.5) 25.7 (17.4-34.1)
65-70 59 (22.3) 26.3 (16.8-35.9)
>70 79 (29.8) 26.1 (19.2-32.9)
Margin involvement <0.001
R0 207 (78.1) 30.0 (25.1-35.0)
R1 42 (15.8) 18.3 (7.6-28.9)
T status 0.003
T1 21 (7.9) 27.2 (15.9-38.5)
T2 64 (24.2) 36.0 (22.3-49.7)
T3 166 (62.6) 22.0 (17.7-26.3)
T4 8 (3.0) 14.7 (7.4-22.0)
LNR <0.001
N0 94 (35.5) 33.6 (30.4-36.8)
?0.2 123 (46.4) 25.7 (17.9-33.6)
>0.2 42 (15.8) 13.6 (7.7-19.4)
Tumor location 0.734
Head 230 (86.8) 26.0 (21.8-30.1)
Body 19 (7.2) 36.0 (10.3-61.7)
Tail 13 (4.9) 34.1 (9.4-58.8)
Tumor size 0.007
?30 mm 135 (51.0) 30.1 (24.8-35.4)
>30 mm 120 (45.0) 20.5 (15.6-25.4)
Preoperative chemo-/radiotherapy 0.573
None 218 (82.3) 25.7 (20.8-30.6)
Yes 46 (17.4) 30.0 (23.7-36.4)
Postoperative chemo-/radiotherapy 0.058
None 86 (32.5) 21.9 (14.5-29.3)
Adjuvant 139 (52.5) 30.1 (24.1-36.0)
Palliative 34 (12.8) 23.9 (15.4-32.5)
Cause of death -
PDAC 202 (76.2) -
Other 10 (3.8) -
Alive 53 (20.0) -
Table 8. Patient characteristics and survival time (months). Median survival
time was assessed with Kaplan-Meier analysis and significance with log-rank
test. (Study IV)
CI, confidence interval; LNR, lymph node ratio; PDAC, pancreatic ductal
adenocarcinoma
55
8.9 Statistics
Statistical analyses were assessed with the IBM Statistical Package for Social
Sciences (SPSS) Statistics 22. We tested normality by the Kolmogorov-
Smirnov test. To detect differences between continuous variables we used the
nonparametric Mann-Whitney U-test, the Kruskall-Wallis test, or the
Wilcoxon’s signed-rank test (paired measurements). Two-tailed Spearman’s
correlations were applied to calculate associations between continuous
variables.  In  the  migration  assay,  confidence  intervals  (CI)  for  fold  change
were  calculated  according  to  the  rules  of  error  propagation  as  asymptotic
confidence intervals. We estimated survival by Kaplan-Meier analysis and the
Log-rank test. Survival was determined from time of pancreatic surgery to
cancer-specific death; the patient was censored at the last follow-up date if no
events  had  occurred.  To  assess  the  significant  differences  in  medians  of
laboratory  values  by  survival  time  (ordinal  scale),  we  used  the  Jonckheere-
Terpstra  test.  Multivariate  modeling  was  conducted  by  means  of  the  Cox
proportional hazards model. A p value <0.05 was considered statistically
significant.
Results
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9 RESULTS
9.1 Characterization of macrophages (Studies I-III)
Isolated monocytes were differentiated into macrophages with either GM-CSF
or M-CSF. The polarization of GM-CSF-differentiated macrophages skewed
more towards type M1, had over 50% of the cells positive to CD86 and CD206.
In contrast, M-CSF-differentiated macrophages, skewed more towards M2,
were  over  50%  positive  to  CD14  (p=0.007  as  compared  to  GM-CSF-
differentiated cells), CD80 (p=0.017), CD86, CD163 (p=0.001), CD206
(p=0.001), and CD209 (p=0.004). Co-culture with pancreatic cancer cells
caused little change in both GM-CSF- and M-CSF-differentiated macrophages’
surface  expression;  only  the  proportion  of  CD16-positive  cells  increased  in
GM-CSF differentiated macrophages:  from 11.2 (±2.6) to 40.6% (±5.7 SEM,
p=0.002) (Table 9).
Macrophage polarization was altered with the additional stimulation. Table 9
shows the proportion of macrophages positive to the different surface markers
with the different stimulations, and the comparisons to respective GM-CSF-
/M-CSF-differentiated macrophages with no additional stimuli (see also
Figures 9A and 9B). In summary, we were able to obtain macrophages with
both inflammatory and anti-inflammatory phenotypes by different
stimulations. In M-CSF-differentiated macrophages, the combination of
inflammatory LPS and anti-inflammatory IL-4 caused mixed effects on
surface protein expression, IL-12 skewed macrophage polarization towards
the inflammatory M1 type, and IL-10 towards the anti-inflammatory M2 type
(data for GM-CSF-differentiated macrophages supplemented with IL-12 are
unpublished results of Salmiheimo et al.). Although having other significant
effects in the cell cultures, IL-6 did not change the surface protein expression
of GM-CSF differentiated macrophages.
Scavenger receptor CD163 (a widely used M2 marker) responded to the stimuli
consistently parallel with the expected polarization of M1/M2, being higher in
M2-polarized macrophages.  It  was higher in M-CSF- (M2) than in GM-CSF
(M1) -differentiated macrophages (p=0.001). It was high also in macrophages
stimulated  with  IL-10  (anti-inflammatory  cytokine),  and  low  with  the
inflammatory IL-12-, IL-4+LPS-, and IL-6-stimulated macrophages.
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Figure 9.  Macrophage characteristics (Studies II and III). A) Characteristics of
differently stimulated GM-CSF (M1)-differentiated macrophages with and without
MiaPaCa-2. *p<0.05 in comparing macrophages alone to correspondingly
differentiated macrophages co-cultured with cancer cells. #p<0.05 in comparing
differentiated to GM-CSF-only macrophages (with or without MiaPaCa-2
accordingly). Error bars show the standard error of the mean (SEM).
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Figure 9. Macrophage characteristics (Studies I-III). B) Characteristics of
differently stimulated M-CSF (M2)-differentiated macrophages with and without
MiaPaCa-2. *p value <0.05 when comparing the macrophages alone to
correspondingly differentiated macrophages co-cultured with cancer cells. #p value
<0.05 when comparing the differentiated to M-CSF only macrophages (with or without
MiaPaCa-2 accordingly). Error bars show the standard error of the mean (SEM).
Results
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9.2 Migration of pancreatic cancer cells (Studies I-III)
 Both GM-CSF- (M1) and M-CSF (M2) -differentiated macrophages caused an
increase in migration rate of pancreatic cancer cells. Hypoxic conditions
elevated  the  migration  rate  of  Panc-1  and  ASPC,  whereas  it  reduced  the
migration rate of MiaPaCa-2; no statistically significant changes occurred in
the migration rate of the metastatic HPAF-II cell line. In hypoxic conditions,
however, GM-CSF-differentiated macrophages caused an increased migration
rate of both of the metastatic cell lines (ASPC and HPAF-II) and reduced the
migration  rate  of  primary  tumor  cell  lines  (Panc-1  and  MiaPaCa-2)  as
compared to rates in cancer-cell- and macrophage co-cultures in standard
conditions (Figure 10).
Figure 10. Migration rate of pancreatic cancer cells on Matrigel and the effect
of co-culturing with GM-CSF-differentiated macrophages and hypoxia (Study I).
Co-culture with macrophages raised the migration rate of all of these four PDAC cell
lines. In hypoxic conditions, the migration rate of primary tumor cell lines (Panc-1 and
MiaPaCa-2) decreased, but it increased in metastatic cells (HPAF-II and ASPC) in
co-cultures with macrophages. *p<0.001 as compared to cancer alone in normal
conditions and #p<0.001 in comparing co-cultures of macrophages and cancer in
normal and hypoxic conditions. Error bars show the standard error of the mean.
Additional stimulation with IL-6, IL-4+LPS, and IL-10 did not significantly
alter the migration rate of MiaPaCa-2 or HPAF-2 cultured alone (p>0.05). In
co-cultures with macrophages, however, there were significant changes
occurred with all of these cytokines. IL-6, IL-4+LPS, IL-12, and P6 reduced
cancer-cell migration rate in co-cultures as compared to co-cultures without
the stimulants. In contrast, IL-10 further raised the migration of pancreatic
cancer cells with macrophages, but not without them. Figures 11 and 12 shows
the migration assay results of Study II and III.
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Figure 11. Migration rates of pancreatic cancer cells on Matrigel in co-cultures
with the macrophages polarized with GM-CSF and IL-6 or M-CSF and IL-4+LPS
(Study II). Both GM-CSF- (polarization skewed towards M1) and M-CSF (polarization
skewed towards M1) -differentiated macrophages caused increased migration rates
of both MiaPaCa-2 and HPAF-II pancreatic cancer cell lines (p<0.001). Adding IL-6
to GM-CSF-differentiated macrophages and IL-4+LPS to M-CSF-differentiated
macrophages, caused the macrophage-induced increase in the migration rate to
reverse. *p<0.05 in compared to cancer cells alone. #p<0.05 in comparing co-cultures
of macrophages and cancer with the added stimulus (IL-6 or IL-4+LPS) to the co-
cultures with only GM-CSF or M-CSF. Error bars show the standard error of the mean.
Figure 12. The migration rate of pancreatic cancer cells on Matrigel in co-
cultures with the macrophages polarized with M-CSF and IL-12, IL-10, or P6
(Study III). IL-12 reduced the migration rate of MiaPaCa-2 with and without
macrophages. IL-10 raised the migration rate of MiaPaCa-2 in co-cultures with
macrophages. P6 inhibited the macrophage-induced increase of the migration rate.
*p<0.05 as compared to cancer cells alone. #p<0.05 in comparing the co-cultures of
macrophages and cancer with the stimulus added (IL-12, IL-10, or P6) to the co-
cultures with only M-CSF. Error bars show the standard error of the mean.
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9.3 Changes in signaling pathways (Studies I-III)
In Study I, we examined expression of ADAM8, ADAM9, ADAM10, ADAM17,
MMP2, MMP9, TIMP1, and TIMP3 with RT-PCR in the pancreatic cancer cells
and compared it with the expression in pancreatic cancer cells co-cultured
with macrophages. Macrophage co-culture activated expression of ADAM8 in
the  primary  cell  lines  Panc-1  and  MiaPaCa-2  but  not  in  the  metastatic  cell
lines. Co-culturing also raised the expression of ADAM10 in MiaPaCa-2 and of
ADAM17 in MiaPaCa-2 and HPAF-II. Macrophages reduced in Panc-1 the
expression of  MMP2, which was undetectable in other cell  lines.  TIMP1 (an
MMP2  inhibitor)  remained  unchanged.  Co-culture  with  macrophages
activated MMP9 expression in all cell lines and activated its inhibitor TIMP3
in all  but HPAF-II.  The macrophage-induced rise in migration rate and the
expression  of  MMP9  in  the  different  cancer  cell  lines  showed  a  positive
correlation (R2=0.93, p=0.03).
By reducing the ADAM8 or MMP9 expression with the siRNA technique, we
were able to reduce the macrophage-induced rise in migration rate in
pancreatic cancer cells (MiaPaCa-2 and Panc-1, p<0.001) (Figure 13). In
contrast,  the  migration  rate  of  single  pancreatic  cancer  cells  with  siRNA
inhibition remained statistically unchanged. The relative reduction in ADAM8
and MMP9 expression by siRNA was confirmed by Western blotting.
Figure 13. Decrease in ADAM8 and MMP9 expression by siRNA inhibited the
macrophage-induced rise in migration rate in Panc-1 and MiaPaCa-2 (Study I).
*p<0.001 as compared to the respective control. Non-targeting siRNA (NT siRNA)
induced no statistically significant changes.
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In Study II, we used a cytokine array panel to detect changes in 36 cytokines
and chemokines and compared the effects of GM-CSF- and M-CSF-
differentiated macrophages and stimulation with IL-4+LPS and IL-6
respectively in single-cultures or in co-cultures with MiaPaCa-2 cells.
In GM-CSF-differentiated macrophages (polarized more towards M1), their
co-culture with pancreatic cancer cells reduced secretion of the inflammatory
cytokines  TNFα (from  1.35%  relative  to  the  positive  control  to  0.68%,
p=0.018) and IL-23 (from 0.94% to 0.58%, p=0.005) and anti-inflammatory
IL-13 (from 1.16% to 0.47%, p=0.010) and IL-1Ra (IL-1 receptor antagonist,
from 37.13% to 2.48%, p<0.001). IL-6 in the co-cultures elevated the secretion
of TNFα (to 1.35% relative to the positive control, p=0.010), IL-23 (1.08%,
p=0.004), and CCL1 (chemokine ligand 1, from 1.02% to 2.41%, p=0.033) as
compared to the co-cultures without IL-6.
In M-CSF-differentiated macrophages (polarized more towards M2) secretion
of IL-1Ra decreased from 35.91% relative to the positive control to 16.34%
(p=0.007). In the co-cultures of M-CSF-differentiated macrophages and
MiaPaCa-2 the supplements IL-4+LPS raised secretion of IL-6 (from 0.75% to
4.91%, p=0.033), CCL1 (from 0.35% to 1.26%, p=0.035), CCL3 (from 1.57% to
4.15%, p = 0.042), CCL4 (from 2.49% to 10.80%, p=0.027), CCL5 (from 9.66%
to 27.87%, p=0.045), INFγ (from 0.69% to 1.24%, p=0.045), and TNFα (from
0.74% to 4.47%, p<0.001).
In Study III, we examined STAT 1-, 3-, 5-, AKT-, and NFkB activation by flow
cytometry in M-CSF-differentiated macrophages (M2) and MiaPaCa-2 cells
and stimulation/inhibition with IL-10, IL-12, and P6. The proportion of STAT
3-, STAT 5-, AKT-, and NFkB-positive macrophages increased significantly
(p<0.005)  in  co-cultures  with  MiaPaCa-2  cells  (Figure  14).  In  macrophage
cultures, IL-10 raised STAT 3, 5, and NFkB, whereas in macrophage-MiaPaCa-
2 co-cultures, IL-10 lowered NFkB (p<0.05). The pan-JAK/STAT inhibitor P6
reduced  STAT  1  and  5,  as  well  as  AKT  activity  in  co-cultures  (p<0.05).  In
MiaPaCa-2  the  co-culture  with  macrophages  activated  STAT  3  from  3.5%
baseline activity to 9.8% ±1.0 SEM (p<0.001). This was reduced to 0.2% ±1.3
SEM  (p<0.001)  positivity  with  P6.  In  MiaPaCa-2,  P6  also  raised  the  NFkB
activity to 11.9% ±1.8 SEM (p=0.0017) in the co-culture with macrophages. IL-
10  and  IL-12  made  no  significant  changes  in  the  intracellular  signaling  of
MiaPaCa-2 cultured alone or in co-cultures with macrophages.
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Figure 14. Intracellular activation of M-CSF-differentiated macrophages (M2) in
response to MiaPaCa-2 and IL-10, IL-12, and P6 measured by flow cytometry.
Co-culture with MiaPaCa-2 activated STAT 1, STAT 3, STAT 5, AKT, and NFkB in
macrophages. IL-10 activated STAT 3, STAT 5, and NFkB in macrophages, and IL-
12 reduced STAT 1 activation and increased STAT 5.  *p<0.05 as compared to
macrophages cultured alone (reference was set to 3.5% activity in non-stimulated
macrophages). #p<0.05 as compared to macrophages in co-culture with MiaPaCa-2
without any additional stimulation.
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9.4 Prognostic significance of preoperative laboratory
markers (Study IV)
The 5-year disease-specific survival was 19% (standard error 2.7%) and overall
survival 17% (2.6%). Preoperatively elevated CRP and low albumin were each
associated with shorter survival time in both univariate (Table 10, Figure 15)
and multivariate analysis (Table 11).  Moreover, the elevated tumor markers
CA19-9 and CEA showed a significant association with worse outcome. CA19-
9 levels associated with patient outcome both in univariate and multivariate
analysis,  CEA  showed  a  significant  association  with  patient  outcome  in  the
multivariate analysis only when categorized according to normal and elevated
(≤5/>5 μg/L) values, but not when serving as a continuous variable (Table 11).
The bilirubin, platelets, and leukocytes that we also determined for Study IV
were not associated with survival in univariate analyses (p>0.1), and therefore
they were excluded from the multivariate model.
Median p (survival
Factor n (IQR) time) HR (95% CI) p (HR)
3.7 (8.4)
?5.0 130 31.8 (25.7–37.9) <0.001 1 <0.001
5.1–15.0 58 26.3 (21.5–31.2) 1.4 (1.02–2.04) 0.040
>15.0 42 14.4 (4.4–24.4) 2.3 (1.6–3.3) <0.001
CA19-9 (kU/L) 133.5 (501.0) <0.001
?37 81 33.5 (25.9-41.1) 1 <0.001
38-554 114 26.0 (20.0-32.0) 1.5 (1.01-2.0) 0.022
?555 60 16.1 (7.4-24.7) 2.1 (1.5-3.1) <0.001
CEA (μg/L) 2.7 (2.7) 0.016
?5.0 205 27.4 (23.7-31.1) 1
>5.0 47 14.4 (22.7-30.0) 1.5 (1.1-2.2) 0.017
Albumin (g/L) 37.0 (4.3)* <0.001
??30.0 16 10.0 (2.9-17.0) 3.0 (1.8-5.0) <0.001
30.1-35.9 83 18.1 (13.1-23.0) 1.6 (1.2-2.2) 0.001
?36.0 160 31.7 (26.6-36.8) 1 <0.001
* mean albumin (standard deviation)
Table 10. Univariate analysis of preoprative laboratory biomarkers' association  with median
survival time (months).
Median survival
time (months)
CRP (mg/L)
IQR, interquartile range; HR, hazard raito; CI, confidence interval; CRP, C-reactive protein; CEA,
carcinoembryonic antigen
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Figure 15. Survival curves. The effect of CRP, albumin, CA19-9, and CEA on
survival of the patients resected for pancreatic ductal adenocarcinoma. Survival
curves determined by Kaplan-Meier analysis, significances by log-rank test.
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The association of CRP, albumin, CA19-9, and CEA with survival time showed
that the higher the median preoperative CRP, CA19-9, and CEA, and the lower
the mean albumin, the shorter was the survival time (Figure 16). Besides CRP,
albumin,  and  the  tumor  markers,  in  the  multivariate  model,  adjuvant
chemotherapy,  margin involvement,  and lymph-node ratio (LNR) showed a
significant association with survival (Table 11). Patients who died of PDAC had
higher median CRP and CA19-9 and lower albumin levels than did those alive
throughout follow-up.
Factor Description HR (95% CI) p value
Age (years) <65/?65 0.97 (0.68-1.38) 0.866
Sex Male/Female 1.27 (0.90-1.79) 0.173
Tumor size (mm) ?30/>30 1.02 (0.71-1.48) 0.906
T status T1-2/T3-4 1.32 (0.90-1.93) 0.16
Adjuvant therapy Yes/No 1.86 (1.29-2.68) 0.001
Margin R0/R1 1.77 (1.15-2.72) 0.009
LNR (0) N0 1 <0.001
LNR N1, ?0.2 1.83 (1.22-2.75) 0.004
LNR N1, >0.2 3.64 (2.08-6.38) <0.001
Albumin (g/L) log 0.18 (0.05-0.75) 0.019
CRP (mg/L) log 1.20 (1.03-1.40) 0.021
CEA (μg/L) log 1.20 (0.93-1.56) 0.168
CA19-9 (kU/L) log 1.11 (1.02-1.21) 0.014
HR, hazard ratio; CI, confidence interval; LNR, lymph-node
Table 11. Multivariate model considering clinically and
statistically important patient characteristics and preoperative
biomarkers (n=189).
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Figure 16. Laboratory data according to survival time. Association of median
CRP, mean albumin, median CA19-9, and median CEA with survival time categorized
as less than 3 months, 3-12 months, 12-24 months, and over 24 months. Patients
with shorter postoperative survival time had higher preoperative median CRP, CA19-
9, and CEA, and lower mean albumin level. Significances determined by the
Jonckheere-Therpstra test.
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GPS and  mGPS both  associated  in  univariate  analysis  with  survival  time  of
patients with PDAC (Table 12, Figure 17). In multivariate analysis considering
age,  sex,  tumor  size,  T  status,  administration  of  adjuvant  therapy,  margin
involvement, LNR, CA19-9, and CEA (Table 11), both GPS score of 1 and mGPS
score of 1 had no statistical significance regarding survival (Table 12). Hazard
ratios  for  both  GPS  2  and  mGPS  2  were  each  2.1,  indicating  that  neither
seemed clearly superior for our study patients in predicting their outcome.
Figure 17. Survival curves by GPS. Association of Glasgow prognostic score (GPS)
and modified Glasgow prognostic score (mGPS) on survival of patients with resected
pancreatic ductal adenocarcinoma. Survival curves (survival time in months after
surgery) by Kaplan-Meier analysis and significance by log-rank test.
Median survival p (survival
Factor n time (95% CI) time) HR (95% CI) p (HR) HR (95% CI) p (HR)
GPS <0.001
0 153 31.7 (26.1-37.4) 1 <0.001 1 0.006
1 67 21.5 (14.6-28.3) 1.6 (1.1-2.2) 0.005 1.2 (0.9-1.8) 0.265
2 33 14.4 (4.3-24.6) 2.3 (1.5-3.4) <0.001 2.1 (1.3-3.4) 0.002
mGPS <0.001
0 194 30.1 (25.4-34.7) 1 <0.001 1 0.008
1 26 20.7 (7.3-34.1) 1.8 (1.1-2.8) 0.012 1.2 (0.7-2.0) 0.547
2 33 14.4 (4.3-24.6) 2.1 (1.5-3.1) <0.001 2.1 (1.3-3.3) 0.002
Univariate model Multivariate model
Table 12. The median survivalt time categorized by the GPS and mGPS. The hazrd ratios (HR) by
the Cox regression model in univariate analysis and in the multivariate model (taking into
account age, sex, tumor size, adjuvant therapy, T-status, lymph-node ratio, CA19-9, and CEA).
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10 DISCUSSION
These  studies  provide  novel  insight  into  the  role  of  inflammation  and
especially macrophages in pancreatic ductal adenocarcinoma (PDAC). The
significant findings include our being able through macrophage polarization
to modify the effect of those macrophages on PDAC cell migration. We showed
that macrophages activate pancreatic cancer cell migration by causing
increases in MMP9 and ADAM8 expression in PDAC cells, and we showed that
supporting the inflammatory microenvironment in PDAC and macrophage co-
cultures had an inhibitory effect on PDAC cell migration. A relevant finding
was also preoperative SIR’s adverse effect on the prognosis of resectable
PDAC.
Macrophages  can,  due  to  their  plasticity,  change  their  phenotype  and
characteristics in response to stimuli in their microenvironment (Rhee 2016).
We observed their polarization by measuring the surface expression of several
surface-protein markers. First, the isolated monocytes must mature into
macrophages, a process which we induced with either GM-CSF or M-CSF. The
original  hypothesis  was  that  GM-CSF  would  polarize  the  macrophages  into
type M1 (inflammatory) and M-CSF into type M2 (anti-inflammatory)
macrophages (Hamilton 2008, Jaguin 2013). However, our study
demonstrated that with these growth factors the polarization was incomplete;
GM-CSF and M-CSF as such were insufficient to skew the macrophages to the
two  extremes  of  macrophage  polarization.  Further,  both  macrophage  lines
promoted cancer cell migration, indicating that PDAC cells skewed the GM-
CSF-differentiated  M1  macrophages  into  type  M2  TAMs.  Co-culturing  the
macrophages with MiaPaCa-2 cancer cells induced surprisingly few changes
in macrophage surface expression. In theory, cancer cells should polarize the
macrophages  towards  a  subtype  of  M2,  and  raise  the  proportion  of  cells
positive to the M2/TAM surface markers CD14, CD163, CD206, and CD209,
while reducing the M1 markers. Instead, after addition of MiaPaCa-2 to GM-
CSF-differentiated macrophages, only the CD16 (M1 marker) decreased; and
in M-CSF-differentiated macrophages, no statistically significant changes
occurred. We were able to change the surface expression of the macrophages
with  added  cytokines,  even  though  polarization  indicated  by  the  surface
markers was somewhat inconsistent with the additional  stimuli.   It  seemed,
though, that scavenger receptor CD163, widely used to differentiate M2 from
M1, responded as expected to the polarization stimuli.
In  the  light  of  our  and  numerous  others’  results,  it  seems  evident  that
macrophages play a critical  role in the regulation and modulation of  cancer
cell migration, which is a key step leading to cancer metastasis (Beuran 2015).
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Our  results  show  that  macrophages  can  either  resist  or  activate  cancer  cell
migration  according  to  the  stimuli  of  their  microenvironment.  That  the
macrophages’  effect  can  be  altered  by  changes  in  the  surrounding  cytokine
profile, even after their maturation, is exciting. This raises the question
whether  modifying  a  patient’s  macrophage  polarization  could  provide  a
suitable target for anti-cancer therapy.
The  inflammatory  cytokines  IL-6  and  IL-12,  typically  produced  by  M1
macrophages, restricted pancreatic cancer cell migration in co-cultures with
macrophages,  and  thus  seemed  to  promote  the  anti-tumor  actions  of  M1
macrophages (Baay 2011).  Conversely,  IL-6 is  a  known activator of  STAT 3,
which in turn promotes cancer-cell proliferation and inhibits cancer-cell
apoptosis (Yu 2009); the inhibition of pancreatic cancer-cell migration in our
study was thus somewhat surprising. The cytokines IL-6, IL-10, and IL-
4+LPS, without the macrophages, left the migration of pancreatic cancer cells
unchanged. IL-10, however, clearly elevated the migration rate of cancer cells
only in co-cultures with macrophages,  indicating that  something changes in
the macrophages that supports the migration of pancreatic cancer cells.
When comparing the effects of macrophages on cancer-cell migration rate, it
seemed that the metastatic cell lines were able to take more advantage of the
macrophages than did the primary-tumor PDAC cell lines. Hypoxia, together
with macrophages, caused significantly increased migration of metastatic cell
lines,  but not of  primary-tumor cell  lines.  In co-cultures with macrophages,
the migration rate of metastatic cell lines increased more than did the rate of
primary-tumor cell lines. Further, the pro-inflammatory microenvironment
(with IL-6 and IL-4+LPS) reversed the macrophage-induced increase in PDAC
cell migration rate more effectively in the primary cell lines. The response to
the additional stimuli varied among different cancer cell lines. Study I showed
that for example the expression of ADAM8 was associated with migration rate
particularly in primary-tumor cell  lines,  but not as closely in metastatic  cell
lines. The differing response of the PDAC cell lines, shown also earlier studies
(Shen 2013), may reflect the heterogeneity of the disease and highlight the
importance of understanding the underlying mechanisms.
The signaling pathways implicated in PDAC cells’ interactions with
macrophages are complex and dependent on many factors. In our studies we
focused  on  ADAMs,  MMPs,  intercellular  cytokines  associated  with
inflammation, and intracellular STAT and NFkB signaling. Significant changes
occurred in all of these signaling pathways. We found that macrophages raised
the migration rate of pancreatic cancer cells by activating their expression of
ADAM8 and MMP9, which participate in ECM remodeling and angiogenesis
(Page-McCaw  2007).  Hypoxia  also  lad  to  increased  MMP9  expression  but
simultaneously induced the expression of its inhibitor TIMP3; it seemed that
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their balance was a critical factor in the migration rate of each cancer cell line.
Depending  on  cancer  type,  MMP9  correlates  in  previous  studies  with  both
better  and  worse  prognosis  and  also  depending  on  whether  MMP9  was
determined  from  peripheral  blood  circulation  or  from  the  tumor  sample
(Scorilas 2001, Grutzmann 2004, Mroczko 2009, Koskensalo 2012). It seems
that while locally in the tumor microenvironment the ECM-degrading MMP9
aids tumor metastasis, it may systemically support inflammatory activation
and thus play a protective role against cancer progression. Levels of MMPs and
TIMPs in the blood circulation increase also in other inflammatory conditions,
and  they  correlate  with  the  severity  of  such  diseases  as  acute  pancreatitis
(Nukarinen 2016).
Cytokine  determination  in  the  co-cultures  of  macrophages  and  pancreatic
cancer  cells  showed  that  cytokine  support  of  the  pro-inflammatory
microenvironment inhibited the macrophage-induced increase in PDAC-cell
migration rate. MiaPaCa-2 cells were able to suppress the inflammatory
cytokines secreted by the GM-CSF-differentiated macrophages. However, with
addition  of  IL-6,  inflammatory-cytokine  production  was  restored  in  the  co-
cultures,  and  the  macrophage-induced  rise  in  PDAC  cell  migration  was
inhibited. The same was observable in the M-CSF-differentiated macrophages;
they had relatively low inflammatory cytokine production to begin with, and
in co-cultures the cancer-cell migration rate was higher, but when we added
IL-4+LPS to the co-cultures, inflammatory cytokine production was
enhanced, and pancreatic cancer cell migration was inhibited. These results
support the theory of the anti-tumor actions of M1 and pro-tumor actions of
M2  macrophages.  This  indicates  that  the  inflammatory  microenvironment
and  the  cytokines  that  the  macrophages  produce  may  be  more  important
determinants of  macrophage polarization than are the surface markers they
express, as also shown elsewhere (Helm 2014).
In  co-cultures  with  macrophages,  P6,  IL-6,  and  IL-4+LPS  promoted  TNFα
secretion, and each of these also inhibited PDAC migration. In contrast, TNFα
and NFkB secretion was reduced in the co-cultures supplemented with IL-10
that promoted cancer-cell migration. TNFα is an immunomodulating cytokine
that regulates apoptosis, growth-factor synthesis, and participates in
inflammatory- and immune responses, having both tumorigenic and anti-
tumor functions. In some murine models, it causes hemorrhagic necrosis in
tumors,  but  its  systemic  use  in  cancer  treatment  is  limited  by  its
ineffectiveness and severe toxicity (Balkwill 2009). Further, the constitutive
production of TNFα by tumor cells has tumor-promoting actions possibly by
its participating in epithelial-to-mesenchymal transition and by recruiting
anti-inflammatory TAMs to the tumor site (Li 2009, Helm 2014).
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Intracellular STAT transcription factors participate in tumor progression and
macrophage differentiation through phosphorylation by JAK-receptors. In
macrophages, the co-culture with pancreatic cancer cells activated STAT 3 and
5, both implicated in cancer progression, as were NFkB and AKT, important
mediators  of  the  immune  system.  Further,  in  MiaPaCa-2,  STAT  3  was
increased  in  the  co-culture  with  macrophages.  STAT  3  suppresses  the
expression of NFkB target genes and thus suppresses inflammatory activation
in cells (Yu 2009), and it has earlier been associated with PDAC invasiveness
(Nagathihalli 2016). P6 reduced STAT 3 in MiaPaCa-2 (but not significantly in
macrophages),  which may lead to inhibited cancer-cell  migration.  However,
although IL-12 inhibited pancreatic cancer-cell migration in co-cultures, STAT
3 activity remained intact, indicating that migration rate can change despite
STAT 3.
Study IV showed the connection between PDAC and inflammation also in vivo
in humans, because CRP and hypoalbuminemia independently associated
strongly with PDAC patients’ post-operative survival. Additionally, the serum
tumor  markers  CA19-9  and  CEA,  which  correlated  with  tumor  size  and  T
status  —thus  possibly  reflecting  an  advancing  stage  of  the  disease—  were
associated with outcome. Tumor markers are associated with advancing stage
of  cancer,  and  their  fluctuations  correlate  with  response  to  treatment  and
disease progression (Goonetilleke 2007). In contrast, elevated CRP had no
significant association with the tumor-related factors that typically associate
with the prognosis (tumor size, T status, LNR). This may indicate that SIR is
activated independent of these factors. What remains uncertain, however, is
whether SIR is  responsible for the worse prognosis  or whether it  is  only an
indicator of a more aggressive cancer.
Our  multivariate  analysis  showed  that,  besides  CRP,  albumin,  CA19-9,  and
CEA, factors associated with survival were LNR, resection margin status, and
adjuvant chemotherapy. These factors, however, have the obvious prognostic
disadvantage of emerging only during or after surgery. This means that they
are undeterminable in planning of the surgery and in evaluation of post-
operational prognosis. Therefore, determination of preoperative CRP,
combined with albumin and tumor markers, may prove helpful for selecting
patients for surgery, although further validation is vital. The International
Study  Group  of  Pancreatic  Surgery  (ISGPS)  has  also  acknowledged  the
importance of SIR in PDAC in their recent guidelines that recommend, in all
patients considered for resection of PDAC, determination of either mGPS or
the NLR (Bockhorn 2014).
Although the  present  study  provides  novel  insight  into  the  complex  field  of
PDAC research, some noteworthy issues remain. First, increased migration
and  invasion  in  the  ECM  indeed  is  the  preliminary  step  in  the  metastasis
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cascade,  but  pancreatic  cancer  progression  comprises  much  more  than
migration. In our experiments, we ignored, however, apoptosis, cell viability,
and proliferation and these would provide further understanding of PDAC
progression.  In  the  co-culture  assays  with  pancreatic  cancer  cells  and
macrophages, where we measured the secretion of cytokines in the culture
medium, it was, unfortunately, undeterminable whether the increased
secretion came from the TAMs or from cancer cells. Further, the problem with
the inhibition of migration rate is that we cannot be sure whether the stimuli
actually affected migration rate through the macrophages; it is also possible
that the stimuli themselves hinder the pancreatic cancer cells’ raising of the
migration rate in response macrophage signals. What was evident, however,
was that IL-10 alone did not change the cancer-cell migration rate, but in co-
cultures  with  macrophages  it  clearly  changed  the  macrophage  phenotype
toward an anti-inflammatory direction, which led to increased pancreatic
cancer-cell migration. In the signaling-pathway assays (assessing ADAMs,
MMPs,  and  STATs),  we  were  able  to  determine  whether  the  pathway  was
activated in pancreatic cancer cells or in macrophages.
Finally,  because all  cell  studies were conducted in in vitro cell  cultures and
with commercial PDAC cell lines, it is impossible to draw direct conclusions
regarding in vivo settings. The validation of our results in non-commercial
cancer cells and in vivo settings is a field for future research. In contrast, the
macrophages in our studies came directly  from healthy human donors,  and
were not immortalized or otherwise genetically modified. Many studies in this
field  uses  commercial  murine  macrophages.  It  is  exceedingly  important  to
create basic knowledge in reproducible settings of the mechanisms underlying
PDAC progression, because the treatment possibilities against metastasis are
currently inadequate; hope exists for finding novel targets for therapy,
possibly by changing the interaction between PDAC and TAMs. Nywening et
al. (2016)  recently  showed  very  promising  results  in  a  phase  1  trial  by
inhibiting CCR2, which recruits TAMs and enhances immune-suppression in
PDAC, in combination with FOLFIRINOX. This further encourages
exploration of the possibilities of TAM-targeting therapies.
Study  IV  is,  to  our  knowledge,  one  of  the  largest  studies  concerning  the
association of resectable PDAC with the prognostic value of SIR. Yet, because
of some missing data among laboratory values and pathologic specimens, the
final multivariate analyses comprised only 189 patients as compared to the 265
originally included. A larger cohort would provide greater reliability, but our
comprehensive and reliable clinical data enhance the value of the study. What
we did not determine was the duration of  the symptoms prior to diagnosis,
data  which  may  correlate  with  PDAC  prognosis  (Porta  2005).  Symptom
duration  may  be  associated  with  development  of  laboratory  abnormalities
(Watanabe 2004) and with survival, as duration may indicate longer disease
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progression. However, the symptoms of pancreatic cancer typically occur as
the disease progresses, with symptoms of early disease often being vague
(Hidalgo 2010, Ryan 2014). This makes it difficult to retrospectively determine
the onset of symptoms, especially in resectable PDAC; for example, back pain
predicts inoperable disease (Ridder 1995).
For the future, Study IV, in concert with the other studies, raises the question
whether patients with preoperative SIR may benefit from treatment with anti-
inflammatory drugs or neoadjuvant therapy. Further, what remains uncertain
is whether SIR is a cause or only an indicator of worse outcome; it would be
interesting to study whether SIR is associated with the pre-diagnostic duration
of symptoms, and if it predicts metastatic disease not yet visible by imaging,
or predicts earlier progression of PDAC.
Between 1981 and 2010, the overall 1-year relative survival rate for pancreatic
cancer has risen from 3% to 7%, and 5-year relative survival from 17% to 28%
(Sun  2014),  indicating  slow  positive  progress  in  the  management  of  this
frightening disease. With the rising incidence of pancreatic cancer, it is now
more important than ever to create novel strategies for PDAC management.
The  introduction  of  new  treatments  has  been  slow,  with  radical  resection
remaining the only possibility for a cure. Yet, some light glimmers at the end
of the tunnel, as cancer research rapidly progresses. Our studies encourage
further exploration of the possibilities of targeting inflammatory processes
and macrophages as possible candidates for anti-cancer therapy.
Conclusions
76
11 CONCLUSIONS
The studies included in this thesis brought novel insight to the association of
pancreatic cancer and inflammation and especially the interaction of
pancreatic cancer cells and tumor-associated macrophages. Macrophages
participate centrally in the regulation and promotion of pancreatic cancer-cell
migration  and  are  potential  targets  for  therapy.  Based  on  these  studies,  we
conclude the following:
1. Hypoxia,  MMP9,  and  ADAM8  have  an  essential  effect  on  the
macrophage-induced increase in pancreatic cancer cell migration.
2. Macrophages can be polarized by various stimuli towards types M1 and
M2  macrophages,  but  their  surface  protein  expression  is  not  always
directly indicative of their impact on pancreatic cancer cell migration;
however, it seems that the more inflammatory the microenvironment,
the more effectively the macrophages inhibit cancer cell migration.
3. Pancreatic cancer cell migration can be both promoted and inhibited by
stimulating the macrophages with differing cytokines.
4. In macrophages, their STAT 1, 3, and 5, as well as NFkB/Akt pathways
were activated by their interaction with PDAC cells. The pan-
JAK/STAT inhibitor P6 inhibited PDAC cell migration.
5. In patients with resectable pancreatic ductal adenocarcinoma, a
preoperative systemic inflammatory response predicts worse
prognosis.
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